Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells
By using a stem cell manufacturing system and a gel culture medium floating culture method, the problems of high cost, low efficiency, and unstable quality in iPS cell production have been solved, achieving efficient and low-cost iPS cell production and differentiation.
Patent Information
- Application Number
- CN202210349694.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2016-08-30
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2036-08-30
AI Technical Summary
Existing technologies for producing induced pluripotent stem cells (iPS cells) suffer from high costs, unstable quality, long production time, high human resource requirements, and low culture efficiency. Furthermore, conventional floating culture systems struggle to maintain the independence and uniformity of cell colonies, resulting in low differentiation efficiency.
A stem cell manufacturing system, including a pre-transfer cell solution delivery channel, an inducer solution delivery mechanism, an inducer transfer device, a cell cluster production device, and a packaging device, is used. This system is combined with floating culture in a gel medium and lipid transfection to transfer reprogramming factor RNA, avoiding agitation and maintaining the independence and homogeneity of cell colonies.
This enables efficient and low-cost production of clinically usable iPS cells, shortening production time, reducing the risk of gene damage, and improving the differentiation efficiency and quality stability of cell colonies.
Smart Images

Figure CN114717183B_ABST
Abstract
Description
[0001] This application is a divisional application of application No. 201680050145.X, filed with the State Intellectual Property Office of China on August 30, 2016, with the invention name “Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells”. Technical Field
[0002] The present invention relates to a cell technology, a pluripotent stem cell manufacturing system, a method for inducing stem cells, a floating culture method for stem cells, a floating culture container for stem cells, a method for producing induced pluripotent stem cells, and a method for producing specific somatic cells from animal cells. Background Art
[0003] Embryonic stem cells (ES cells) are stem cells set up from people or mouse early embryos.ES cells show pluripotency, and this pluripotency allows them to be divided into each cell in the organism from which they are derived.At present, human ES cells are utilized to treat many diseases in cell transplantation therapy, including Parkinson's disease, juvenile diabetes and leukemia.However, there are shortcomings in the transplantation of ES cells.It should be noted that the transplantation of ES cells may trigger immune rejection in a manner similar to the rejection that occurs after unsuccessful organ transplantation.In addition, the use of the ES cells set up by destroying the human embryo has caused a large amount of criticism and strong opposition based on ethics.
[0004] Under the background of these situations, Kyoto University professor Shinya Yamanaka successfully established induced pluripotent stem cells (iPS cells) by transferring four genes of Oct3 / 4, Klf4, c-Myc and Sox2 into somatic cells. For this reason, he was awarded the 2012 Nobel Prize in Physiology or Medicine (see, for example, Patent Document 1). iPS cells are ideal pluripotent cell types because they avoid both immune rejection and ethical issues. Therefore, it is expected that iPS cells will be used for cell transplantation therapy.
[0005] (Background Art of Method for Inducing Stem Cells, Floating Culture Method for Stem Cells, and Floating Culture Container for Stem Cells)
[0006] Induced pluripotent stem (iPS) cells have two characteristic potentials. The first is the potential to generate all somatic cells in the body. The second is the ability to proliferate semi-permanently. Because iPS cells exhibit these two potentials, by producing iPS cells from an individual's own body cells and converting these cells into somatic cells of interest, they will be used for transplantation therapy without rejection. Therefore, iPS cells have great prospects in the field of regenerative medicine.
[0007] (Background Art of Method for Producing Induced Pluripotent Stem Cells)
[0008] Induced pluripotent stem (iPS) cells have two characteristic potentials. The first is the potential to generate all somatic cells in the body. The second is the ability to proliferate semi-permanently. Because iPS cells exhibit these two potentials, they can be used for transplantation therapy without rejection. This can be achieved by producing iPS cells from an individual's own body cells and converting these cells into somatic cells of interest. Therefore, iPS cells have great prospects in the field of regenerative medicine.
[0009] Several methods for producing iPS cells have been established. Typical examples of methods for producing iPS cells include methods using retroviruses or lentiviruses, and methods using episomal vectors.
[0010] The method using retrovirus or slow virus will be described. Retrovirus or slow virus can infect somatic cells so that the gene encoding reprogramming factor is transferred into the cell. In addition, retrovirus or slow virus can insert reprogramming factor into the genome of somatic cells to induce the stable expression of reprogramming factor in cells.
[0011] However, the method of relying on the use of retrovirus or slow virus is problematic. First, the reprogramming factor is inserted into the genome of the somatic cell, which damages the existing gene or promoter, and thus can trigger the tumorigenesis of the cell. Secondly, the reprogramming factor inserted into the genome can be reactivated after the iPS cell is converted into a somatic cell. Therefore, the cells derived from iPS cells for transplantation have the risk of tumorigenesis. In fact, it has been confirmed that the reprogramming factor of transfer is reactivated in the somatic cells of the mouse model, and the cell becomes cancerous (see, for example, non-patent literature 1).
[0012] In addition, iPS cells produced using retroviruses or lentiviruses may retain residual viruses. When such iPS cells are transplanted into patients, residual viruses can infect patients. Therefore, these iPS cells cannot be used for transplantation. For reference, since gene therapy is performed for X-linked combined immunodeficiency (X-SCID), in which the γc gene is transferred to hematopoietic stem cells via a retroviral vector, patients have been informed that they suffer from leukemia due to the activation of the LM02 gene caused by the insertion of the vector (see, for example, non-patent documents 2 and 3).
[0013] Therefore, the use of iPS cells produced using retroviruses or lentiviruses in clinical therapy is problematic.
[0014] Next, the method using episomal vector will be described. In order to overcome the problem of gene transfer method using retrovirus or slow virus, the method using episomal vector to produce iPS cell has been developed (see, for example, non-patent literature 4). Episomal vector is a plasmid. Episomal vector replicates simultaneously with cell division. Unlike retrovirus and slow virus, reprogramming factor is not inserted into the gene of somatic cell. Due to this feature, episomal vector can realize long-term intracellular expression of reprogramming factor to generate iPS cell without inserting gene into deoxyribonucleic acid (DNA) of targeting somatic cell.
[0015] However, methods using episomal vectors are also problematic. First, electroporation is required to transfer genes into cells, which greatly damages the cells; even during a single electroporation event, a high percentage of cells are damaged. Second, electroporation cannot be performed repeatedly. In addition, methods using episomal vectors determine that the gene transfer efficiency is lower than that of retroviral / lentiviral based methods.
[0016] Recent studies have revealed that the transfer of episomal vectors can result in fragments of the vector DNA being inserted into the genes of the target iPS cells. Therefore, even when episomal vectors are used, the resulting iPS cells will most likely contain vector fragments that have been inserted into their genome. Therefore, the clinical application of such iPS cells remains controversial.
[0017] For these reasons, iPS cells produced using episomal vectors are also difficult to use clinically.
[0018] Because the methods using retroviruses or lentiviruses and the methods using episomal vectors as described above are problematic, methods using RNA to produce iPS cells have been proposed (see, for example, Non-Patent Document 6). However, although successful iPS cell induction has been obtained using fetal or newborn fibroblasts, there are no reports on the successful induction of iPS cells from adult-derived somatic cells using RNA. Therefore, unless iPS cells can be produced from adult-derived somatic cells, their clinical application is difficult.
[0019] In addition, in order to collect the fibroblasts necessary for the production of iPS cells, a 1 square centimeter piece of skin needs to be harvested. This places a great burden on the skin donor. After the excision, the fibroblast culture line must be established through expansion culture. As these fibroblasts proliferate during the expansion process, they are likely to incur genomic damage and / or chromosomal aberrations.
[0020] (Background Art of Method for Producing Specific Somatic Cells from Animal Cells)
[0021] Induced pluripotent stem cells (iPS cells) can generate every somatic cell in the body. Therefore, iPS cells, which can be converted into various types of somatic cells or tissues, are expected to be used in cell transplantation therapy and drug development research. For example, in 2014, retinal cells produced from iPS cells were used for transplantation therapy. Many projects are underway around the world to generate brain cells (and cells of various other organs) from iPS cells for subsequent use in transplantation therapy.
[0022] To date, various methods have been developed to convert iPS cells into somatic cells. However, in order to use iPS cells for transplantation therapy, an efficient method for inducing iPS cell differentiation is very important. Specifically, it is necessary to develop an instrument for inducing iPS cells to differentiate into somatic cells in order to improve the efficiency and accuracy of inducing differentiation. Such an instrument should produce functional somatic cells suitable for transplantation therapy.
[0023] The conventional method of inducing iPS and ES cells to differentiate into somatic cells relies on various combinations and concentrations of growth factors, hormones and / or small molecules to manipulate the fate of cells in an attempt to recapitulate the process of natural development. However, the natural development that occurs in vivo is difficult to replicate in vitro, and has low efficiency. In addition, in the human body, the induced differentiation of iPS cells to human body cells requires a longer time than in mice. For example, it takes at least three months to produce mature neuronal cells. In addition, the efficiency of induced differentiation is very different between ES / iPS cell lines, resulting in problems such as the uneven nature of induced somatic cells. When multiple ES colonies from the same source produce different phenotypes with the same chemical treatment, this confirms this phenomenon. Some colonies in these colonies differentiate into spleen cells, while others become cardiac cells, thus showing that the differentiation potential between colonies is different (see, for example, non-patent literature 6). In addition, when attempting to differentiate a large number of iPS and ES cell types into neuronal cells using a method called serum-free floating culture of rapidly reaggregated embryoid body aggregates (SFEBq), it was found that although the iPS cells and ES cells were cultured in a serum-free medium without neural differentiation substances, some iPS and ES colonies were difficult to successfully convert into neuronal cells (see, e.g., Non-Patent Document 7).
[0024] Specifically, it has been confirmed that cells induced to differentiate from human ES / iPS cells by methods using hormones or chemicals are similar to fetal somatic cells in the initial stage. In addition, it is very difficult to induce ES / iPS cells to differentiate into adult mature somatic cells, and long-term culture of several months is required. However, for drug discovery or medical transplantation of individuals who have completed development, it is crucial to produce somatic cells that are equivalent to the age of these individuals.
[0025] Neuronal cells include various cell subtypes. The method of using hormones or chemicals to induce ES / iPS cells to differentiate into specific neuronal subtypes does not produce homogenous cell populations. Therefore, it is not possible to achieve drug discovery screening specific to specific neuronal cell subtypes. Therefore, the effectiveness of drug discovery screening is low. In addition, with regard to medical transplantation, the different neuronal cell subtypes required for disease treatment cannot be enriched for transplantation.
[0026] In contrast, a method for producing interested somatic cells by directly transferring a gene containing information for generating a specific somatic cell's property into an ES / iPS cell using a virus has been proposed. This method makes it possible to specifically produce mature neuronal cells in a much shorter time (two weeks) than the aforementioned method that relies on using hormones or chemicals. For example, homogeneous excitatory neuron colonies can be obtained by transfecting specific genes into ES / iPS cells. Therefore, it is believed that drug discovery screening of specific neuronal cell subtypes can be achieved. Similarly, for medical transplantation, specific neuronal cell subtypes can be enriched and transplanted to treat diseases.
[0027] However, the method of using viruses to express specific genes to induce stem cell differentiation into somatic cells inserts the gene into the genome of ES / iPS cells and damages endogenous genes. Therefore, it is disadvantageous that drug discovery screening is not necessarily accurate, and transplantation leads to the risk of tumorigenesis (see, for example, non-patent literature 8 and 9).
[0028] [Citation list]
[0029] [Patent Document]
[0030] [Patent Document 1] Japanese Patent No. 4183742
[0031] [Non-patent literature]
[0032] [Non-patent document 1] Nature, Vol. 448, pp. 313-317
[0033] [Non-patent document 2] The New England Journal of Medicine, Vol. 346: 1185-1193, 2002
[0034] [Non-patent document 3] Nature, Vol. 302: 415-419, 2003
[0035] [Non-patent document 4] Nature, Vol. 324: 797-801, 2009
[0036] [Non-patent document 5] Journal of the Japan Academy, Series B, Physical and Biological Sciences, 2009; Vol. 85 (No. 8): 348-62
[0037] [Non-patent document 6] Nature Biotechnology, Vol. 26 (Issue 3): 313-315, 2008
[0038] [Non-patent document 7] Proceedings of the National Academy of Sciences of the United States of America, Vol. 111: 12426-12431, 2014
[0039] [Non-patent document 8] The New England Journal of Medicine, Vol. 346: 1185-1193, 2002
[0040] [Non-patent document 9] Nature, Vol. 302: 415-419, 2003 Summary of the invention
[0041] [Technical issues]
[0042] Induced stem cells, such as iPS cells, are established by transferring inducers such as genes into cells. These cells are then expanded and cultured and cryopreserved. However, the production and industrialization of clinical iPS cells (e.g., GLP or GMP grade) have the following problems:
[0043] 1) Cost
[0044] Clinical iPS cells need to be produced and stored in a completely clean and sterile "clean room". However, maintaining the required cleanliness is very expensive. Therefore, the production of iPS cells is expensive, which is a major obstacle to industrialization.
[0045] 2) Quality
[0046] The process from establishing stem cells to preserving them is complicated and requires many manual techniques. In addition, the production of stem cells depends in part on the skills of the operator. Therefore, the quality of iPS cells can vary depending on the producer or experimental batch.
[0047] 3) Time
[0048] To prevent cross contamination with iPS cells from individuals other than the specific donor, only iPS cells from a single person are produced in a clean room at any given time. In addition, the establishment and quality assessment of iPS cells takes a long time. Because iPS cells are produced for only one individual at a time in each room, it takes a long time to produce iPS cells for many individuals.
[0049] 4) Human Resources
[0050] As mentioned above, at present, the production of iPS cells depends largely on manual processes, and only a few technicians have the necessary skills to produce clinical iPS cells.
[0051] A series of procedures from establishing stem cells to their preservation are complicated, and this complexity is disadvantageous. In response to this, an object of the present invention is to provide a stem cell production system that makes it possible to produce stem cells.
[0052] (About the purpose of the method for inducing stem cells, the floating culture method for stem cells, and the floating culture container for stem cells)
[0053] The cultivation of iPS cells in an adherent culture system requires a culture dish and therefore requires a very large space, resulting in poor culture efficiency. After inducing iPS cells or during their amplification culture, iPS cells must be separated from the culture dish. However, the process of separating iPS cells from the culture dish greatly damages the iPS cells. In addition, these procedures are complicated and not suitable for mechanization.
[0054] In the case of preparing feeder cells derived from mice, producing and amplifying iPS cells on a feeder cell layer in a culture dish, iPS cells are contaminated by components derived from animals. Therefore, iPS cells co-cultured with feeder cells are not suitable for clinical use. Alternatively, producing and amplifying iPS cells in the absence of feeder cells (without feeder cells) puts pressure on iPS cells. This pressure makes it possible for iPS cells to develop abnormal karyotypes or chromosome damage. In addition, when feeder cells are not used, special coatings must be applied to the culture dish, which makes the procedure more complicated.
[0055] In the case of culturing iPS cells in an adherent culture system, iPS cells can proliferate only two-dimensionally, and thus disadvantageously exhibit poor growth efficiency.
[0056] In contrast, it is possible to culture iPS cells in a three-dimensional culture (floating culture) system. However, in conventional floating culture systems, the culture fluid must be stirred continuously to prevent the iPS cells from sinking. However, when the culture fluid is stirred, the iPS cells collide with each other and are thereby damaged. This disadvantageously leads to cell death or karyotype abnormalities.
[0057] In conventional floating culture systems, iPS cells randomly aggregate and combine with each other to form cell clusters (colonies) of various sizes. Therefore, a uniform size distribution cannot be maintained between colonies. If the colonies become too large, nutrients or growth factors cannot diffuse to the cells in the center of the colonies, which leads to differentiation or cell death of these innermost cells. On the contrary, if the colonies are too small, they are not suitable for subculture.
[0058] iPS cells are derived from a single somatic cell. Therefore, each iPS cell line may have different properties to a small extent. Therefore, it is very important to culture each colony independently and establish a separate iPS cell line. In this regard, when culturing iPS cells in a floating culture system, it is necessary to ensure that the colonies of iPS cells grow independently and are separated from each other.
[0059] In the adherent culture system, iPS cells, each derived from a single somatic cell, independently form colonies. However, as described above, in conventional floating culture systems, iPS cells randomly aggregate with each other to form colonies. Therefore, colonies produced in conventional floating systems cannot maintain clonality. Therefore, attempts to induce and culture iPS cells via conventional floating culture systems have not yet successfully produced iPS colonies derived from individual cells. Accordingly, conventional floating culture methods that make it possible to establish independent iPS cell lines have not yet been developed.
[0060] Therefore, another object of the present invention is to provide a method of inducing stem cells, a floating culture method for stem cells, and a floating culture container for stem cells, which make it possible to culture iPS cells with isolated and separated colonies.
[0061] (Objective of the method for producing induced pluripotent stem cells)
[0062] Another object of the present invention is to provide a method for producing clinically usable stem cells.
[0063] (Objective of the method for producing specific somatic cells from animal cells)
[0064] Another object of the present invention is to provide a method for efficiently producing a specific type of somatic cell from another type of animal cell within a short period of time and without causing genetic damage.
[0065] [Solution to the problem]
[0066] One aspect of the present invention provides a stem cell manufacturing system, comprising: (a) a pre-transfer cell solution sending channel, through which a solution containing cells flows; (b) an inducer solution sending mechanism, which sends a pluripotency inducer into the pre-transfer cell solution sending channel; (c) an inducer transfer device, which is connected to the pre-transfer cell solution sending channel and transfers the pluripotency inducer into cells to produce cells carrying the inducer; (d) a cell cluster production device, which cultures the cells carrying the inducer to produce a plurality of cell clusters composed of stem cells; (e) a packaging device, which sequentially packages a plurality of cell clusters; and (f) a container, which accommodates the pre-transfer cell solution sending channel, the inducer solution sending mechanism, the inducer transfer device, the cell cluster production device and the packaging device.
[0067] The above-mentioned stem cell production system may further include a separation device that separates cells from blood, wherein a solution containing cells separated by the separation device may flow through the pre-transfer cell solution sending channel.
[0068] In the above-mentioned stem cell manufacturing system, the cell cluster production device may include: a reprogramming culture device, which cultures cells carrying inducers produced by the inducer transfer device; a first segmentation mechanism, which segments the cell cluster composed of stem cells established by the reprogramming culture device into multiple cell clusters; an expansion culture device, which amplifies and cultures the multiple cell clusters divided by the first segmentation mechanism; a second segmentation mechanism, which segments the cell cluster composed of stem cells amplified and cultured by the expansion culture device into multiple cell clusters; and a cell cluster conveying mechanism, which sequentially conveys the multiple cell clusters into the packaging device.
[0069] The reprogramming culture device may include a first culture fluid supply device and an expansion culture device, wherein the first culture fluid supply device supplies cells carrying inducers with culture fluid, and the expansion culture device may include a second culture fluid supply device, wherein the second culture fluid supply device supplies multiple cell clusters with culture fluid.
[0070] The above-mentioned stem cell manufacturing system may also include: a reprogramming culture photography device, which photographs cells cultured by the reprogramming culture device; and an expansion culture photography device, which photographs cells cultured by the expansion culture device, wherein colorless culture fluid can be used in the reprogramming culture device and the expansion culture device.
[0071] In the above-mentioned stem cell production system, the inner wall of the channel for sending the cell solution before transfer may be non-adhesive to the cells.
[0072] In the above-mentioned stem cell production system, the pre-transfer cell solution sending channel and the inducer solution sending mechanism may be disposed on the substrate.
[0073] In the above-mentioned stem cell manufacturing system, the packaging device may freeze the cell clusters using a Peltier device or liquid nitrogen. Alternatively, the packaging device may freeze the cell clusters by a freezing method such as vapor compression or vapor absorption.
[0074] The stem cell production system may further include an air purification device for purifying the gas in the container.
[0075] The stem cell production system may further include a temperature control device for controlling the temperature of the gas in the container.
[0076] The stem cell production system may further include a carbon dioxide concentration control device for controlling the carbon dioxide concentration of the gas in the container.
[0077] The stem cell production system may further include a sterilization device for performing dry heat sterilization or gas sterilization on the interior of the container.
[0078] In the above-mentioned stem cell manufacturing system, the inducer solution sending mechanism, the inducer transfer device, the cell cluster production device and the packaging device can be regulated by the server based on the operating procedure, and the server can monitor whether the inducer solution sending mechanism, the inducer transfer device, the cell cluster production device and the packaging device are operated based on the operating procedure, and make operation records.
[0079] The above-mentioned stem cell production system may further include a device for transferring an inducer into the stem cells to differentiate the stem cells into somatic cells.
[0080] One aspect of the present invention provides a method of inducing stem cells, comprising inducing stem cells from somatic cells cultured in a floating manner in a gel medium.
[0081] In the above method for inducing stem cells, the gel medium may not be stirred. The gel medium may be a medium gelled with deacetylgellan gum.
[0082] In the above method for inducing stem cells, the gel medium may not contain growth factors. Alternatively, the gel medium may contain growth factors at a concentration of 40% by weight or less.
[0083] In the above method for inducing stem cells, the gel medium may not contain bFGF. The gel medium may include human ES / iPS medium.
[0084] One aspect of the present invention also provides a floating culture method for stem cells, comprising floating culture of stem cells in a gel culture medium without growth factors.
[0085] One aspect of the present invention also provides a floating culture method for stem cells, comprising floating culture of stem cells in a gel culture medium containing growth factors at a concentration of 40 wt % or less.
[0086] One aspect of the present invention also provides a floating culture method for stem cells, comprising floating culture of stem cells in a gel culture medium without bFGF.
[0087] One aspect of the present invention also provides a floating culture method for stem cells, comprising floating culture of stem cells in a gel culture medium containing bFGF at a concentration of 400 μg / L or less.
[0088] In the above-mentioned floating culture method for stem cells, the gel medium may not be stirred. The gel medium may be a medium gelled with deacetyl gellan gum. The gel medium may contain a ROCK inhibitor. The concentration of stem cells in the gel medium may be 0.1×10 5 cells / mL or higher.
[0089] The above-mentioned floating culture method for stem cells may further include dissociating the stem cells into single cells before the floating culture, and placing the stem cells dissociated into single cells in the gel culture medium.
[0090] In the floating culture of the above-mentioned floating culture method for stem cells, single cells can form colonies while maintaining their clonality.
[0091] The above-mentioned floating culture method for stem cells may further include, before the floating culture, using a grid plate hanging drop culture of the stem cells to form colonies, and placing the formed colonies in a gel culture medium.
[0092] In the above-mentioned floating culture method for stem cells, the stem cells can proliferate while maintaining their undifferentiated state.
[0093] One aspect of the present invention also provides a floating culture container for stem cells, comprising: a dialysis tube that contains stem cells and a gel culture medium; and a container that contains the dialysis tube, wherein the gel culture medium is placed around the dialysis tube.
[0094] In the above-mentioned floating culture container for stem cells, the molecular weight cutoff of the dialysis tube may be 0.1 kDa or more. The dialysis tube may be made of at least one selected from cellulose ester, cellulose ester derivative, regenerated cellulose and cellulose acetate.
[0095] One aspect of the present invention also provides a floating culture method for stem cells, comprising: placing stem cells and gel culture medium in a dialysis tube; placing the dialysis tube in a container; placing the gel culture medium around the dialysis tube in the container; and floating culture stem cells in the gel culture medium in the dialysis tube. The order of placing the stem cells and gel culture medium in the dialysis tube, placing the dialysis tube in the container, and placing the gel culture medium around the dialysis tube in the container is not particularly limited. For example, the dialysis tube can be placed in the container, and then the stem cells and gel culture medium can be placed in the dialysis tube.
[0096] In the above-mentioned floating culture method for stem cells, the molecular weight cutoff of the dialysis tube may be 0.1 kDa or greater. The dialysis tube may be made of at least one selected from cellulose ester, cellulose ester derivative, regenerated cellulose and cellulose acetate.
[0097] In the above-mentioned floating culture method for stem cells, the gel culture medium around the dialysis tube may be supplemented with a ROCK inhibitor. The gel culture medium may not be stirred. The gel culture medium may be a culture medium gelled with deacetyl gellan gum.
[0098] In the above-mentioned floating culture method for stem cells, the gel medium may not contain growth factors. Alternatively, the gel medium may contain growth factors at a concentration of 40% by weight or less.
[0099] In the above-mentioned floating culture method for stem cells, the gel medium may not contain bFGF.
[0100] In the above-mentioned floating culture method for stem cells, the concentration of stem cells in the gel culture medium can be 0.1×10 5 cells / mL or higher.
[0101] The above-mentioned floating culture method for stem cells may further include, before the floating culture, dissociating the stem cells into single cells, and placing the stem cells dissociated into single cells in a gel culture medium.
[0102] In the floating culture of the above-mentioned floating culture method for stem cells, single cells can form colonies while maintaining their clonality.
[0103] The above-mentioned floating culture method for stem cells may further include, before the floating culture, using a grid plate hanging drop culture to culture the stem cells to form colonies, and placing the formed colonies in a gel culture medium.
[0104] In the above-mentioned floating culture method for stem cells, the stem cells can proliferate while maintaining their undifferentiated state.
[0105] The above-mentioned floating culture method for stem cells may further include replacing the gel medium around the dialysis tube in the container with fresh gel medium.
[0106] The above-mentioned floating culture method for stem cells may further include replenishing the gel culture medium around the dialysis tube in the container with fresh gel culture medium.
[0107] In the above-mentioned floating culture method for stem cells, the gel culture medium in the dialysis tube may not be replaced. The gel culture medium may include human ES / iPS culture medium.
[0108] One aspect of the present invention also provides a method for inducing stem cells by floating, comprising: placing somatic cells and gel culture medium in a dialysis tube; placing the dialysis tube in a container; placing the gel culture medium around the dialysis tube in the container; and inducing stem cells from the somatic cells in the gel culture medium floating in the dialysis tube. The order of placing the somatic cells and gel culture medium in the dialysis tube, placing the dialysis tube in the container, and placing the gel culture medium around the dialysis tube in the container is not particularly limited. For example, the dialysis tube can be placed in the container, and then the somatic cells and gel culture medium can be placed in the dialysis tube.
[0109] In the above method of inducing stem cells by floating, the molecular weight cutoff of the dialysis tube may be 0.1 kDa or more. The dialysis tube may be made of at least one selected from cellulose ester, cellulose ester derivative, regenerated cellulose and cellulose acetate.
[0110] In the above-mentioned method for inducing stem cells by floating, the gel medium may not be stirred. The gel medium may be a medium gelled with deacetylgellan gum.
[0111] In the above-mentioned method of inducing stem cells by floating, the gel medium may not contain growth factors.
[0112] In the above-mentioned method of inducing stem cells by floating, the gel medium may not contain bFGF.
[0113] The above-mentioned method of inducing stem cells by floating may further include dissociating the somatic cells into single cells before floating culture, and placing the somatic cells dissociated into single cells in a gel culture medium.
[0114] In the floating culture of the above-mentioned method of inducing stem cells by floating, single cells can form colonies while maintaining their clonality.
[0115] The above-mentioned method of inducing stem cells by floating may further include replacing the gel medium around the dialysis tube in the container with fresh gel medium.
[0116] The above-mentioned method of inducing stem cells by floating may further include replenishing the gel medium around the dialysis tube in the container with fresh gel medium.
[0117] In the above-mentioned method of inducing stem cells by floating, the gel medium in the dialysis tube may not be replaced. The gel medium may include human ES / iPS medium.
[0118] One aspect of the present invention also provides a method for producing induced pluripotent stem cells, comprising: preparing somatic cells; and transferring reprogramming factor RNA into the somatic cells by lipid transfection.
[0119] In the above-mentioned method for producing induced pluripotent stem cells, the somatic cell may be a blood cell. The blood cell may be a monocyte. The blood cell may be a hematopoietic stem / progenitor cell. The blood cell may be CD34 positive. The blood cell may be a blood cell separated under the condition that the cell is CD34 positive. The blood cell may be CD3 positive. The blood cell may be separated under the condition that the cell is CD3 positive.
[0120] In the above method for producing induced pluripotent stem cells, the reprogramming factor RNA may include Oct3 / 4 mRNA, Sox2 mRNA, Klf4 mRNA and c-Myc mRNA. The reprogramming factor RNA may also include at least one selected from the group consisting of GLIS1 mRNA, FOXH1 mRNA, L-MYC mRNA and p53-dn mRNA. The reprogramming factor RNA may also include LIN28A mRNA or LIN28B mRNA.
[0121] In the above-mentioned method for producing induced pluripotent stem cells, an siRNA lipofection reagent or an mRNA lipofection reagent can be used for lipofection with reprogramming factor RNA.
[0122] In the above-mentioned method for producing induced pluripotent stem cells, at least one selected from Lipofectamine(R) RNAiMAX transfection reagent, Lipofectamine(R) MessengerMAX transfection reagent, Stemfect(R) RNA transfection reagent and ReproRNA(R) transfection reagent can be used for lipid transfection with reprogramming factor RNA.
[0123] In the above method for producing induced pluripotent stem cells, the number of blood cells used for lipid transfection with reprogramming factor RNA may be 1 to 1×10 8 Cells. The amount of reprogramming factor RNA used for lipid transfection with reprogramming factor RNA can be 5ng to 50μg each time. The amount of lipid transfection reagent used for lipid transfection with reprogramming factor RNA can be 0.1μL to 500μL each time. Lipofection with reprogramming factor RNA can be performed for 0.1 hours or longer and 24 hours or shorter each time. Lipofection with reprogramming factor RNA can be performed multiple times.
[0124] In the above-mentioned method for producing induced pluripotent stem cells, the medium used for lipid transfection with reprogramming factor RNA may be Opti-MEM(R).
[0125] The above method for producing induced pluripotent stem cells may further include separating mononuclear cells from the blood using a filter.
[0126] One aspect of the present invention also provides a method for producing specific somatic cells from animal cells, comprising: preparing animal cells; and transferring inducer RNA into the animal cells by lipid transfection to differentiate the animal cells into somatic cells.
[0127] In the above method for producing specific somatic cells from animal cells, the animal cells may be stem cells. The stem cells may be induced pluripotent stem cells. The stem cells may be iPS cells. The stem cells may be embryonic stem cells.
[0128] In the above method for producing specific somatic cells from animal cells, the animal cells may be human fibroblasts. Alternatively, the animal cells may be blood cells.
[0129] In the above-mentioned method for producing specific somatic cells from animal cells, the inducer RNA may include mRNA corresponding to a drug resistance gene.
[0130] The above-mentioned method for producing specific somatic cells from animal cells may further comprise selecting cells showing drug resistance after lipid transfection.
[0131] In the above method for producing specific somatic cells from animal cells, the inducer RNA may include mRNA corresponding to a puromycin resistance gene.
[0132] The above-mentioned method for producing specific somatic cells from animal cells may further comprise selecting cells that show puromycin resistance after lipid transfection.
[0133] In the above method for producing specific somatic cells from animal cells, the somatic cells may be neuronal cells. The inducer RNA may include Ngn2 mRNA. The induced neuronal cells may be Ngn2 positive. The induced neuronal cells may be β-III Tubulin, MAP2, PsA-NCAM or vGlut positive.
[0134] In the above-mentioned method for producing specific somatic cells from animal cells, MessengerMAX(R) can be used in lipid transfection with inducer RNA.
[0135] In the above method for producing specific somatic cells from animal cells, the number of cells used for lipid transfection with inducer RNA may be 1×10 4 Up to 1×10 8 The amount of the inducer RNA used for lipid transfection with the inducer RNA may be 200 ng to 5000 ng each time. The amount of the lipid transfection reagent used for lipid transfection with the inducer RNA may be 0.1 μL to 100 μL each time.
[0136] In the above-mentioned method for producing specific somatic cells from animal cells, the medium used for lipid transfection with inducer RNA may be Opti-MEM(R).
[0137] In the above-mentioned method for producing specific somatic cells from animal cells, the animal cells can be differentiated into somatic cells within 10 days from lipid transfection with inducer RNA.
[0138] In the above-mentioned method for producing specific somatic cells from animal cells, the transfer of inducer RNA into animal cells by lipid transfection can be repeated multiple times.
[0139] In the above-mentioned method of producing specific somatic cells from animal cells, the animal cells may be cultured on a substrate coated with a basement membrane matrix.
[0140] In the above method for producing specific somatic cells from animal cells, the animal cells may be cultured in a medium containing B18R. Alternatively, the animal cells may be cultured in a medium not containing B18R.
[0141] [Beneficial Effects of the Invention]
[0142] The present invention makes it possible to provide a stem cell production system capable of producing stem cells.
[0143] (Beneficial effects of method for inducing stem cells, floating culture method for stem cells, and floating culture container for stem cells)
[0144] The present invention makes it possible to provide a method of inducing stem cells, a floating culture method for stem cells, and a floating culture container for stem cells, which are capable of culturing iPS cells with colonies of iPS cells separated.
[0145] (Beneficial effects of the method for producing induced pluripotent stem cells)
[0146] The present invention makes it possible to provide a method for producing clinically usable induced pluripotent stem cells.
[0147] (Beneficial effects of the method for producing specific somatic cells from animal cells)
[0148] The present invention makes it possible to provide a method for producing specific somatic cells from animal cells, which is capable of efficiently producing specific somatic cells in a short time without damaging the genes of the animal cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0149] [ Figure 1 ] Figure 1 is a schematic diagram of a stem cell manufacturing system according to an embodiment of the present invention.
[0150] [ Figure 2 ] Figure 2 is a schematic cross-sectional view of an example of a post-transfer cell solution sending channel in the stem cell production system according to an embodiment of the present invention.
[0151] [ Figure 3 ] Figure 3 is a schematic cross-sectional view of an example of a post-transfer cell solution sending channel in the stem cell production system according to an embodiment of the present invention.
[0152] [ Figure 4 ] Figure 4 Schematic diagram of a culture bag used in a stem cell manufacturing system according to an embodiment of the present invention.
[0153] [ Figure 5 ] Figure 5 is a schematic diagram showing a floating culture container for stem cells according to a second embodiment of the present invention.
[0154] [ Figure 6 ] Figure 6 is a photograph of a colony of iPS cells according to Example 1.
[0155] [ Figure 7] Figure 7 is a photograph of a colony of iPS cells according to Example 1.
[0156] [ Figure 8 ] Figure 8 is a photograph of a colony of iPS cells according to Example 1.
[0157] [ Fig. 9 ] Fig. 9 is a diagram showing the differentiation state of a colony of iPS cells according to Example 1.
[0158] [ Fig.10 ] Fig.10 is a photograph of a colony of iPS cells according to Example 2.
[0159] [ Fig.11 ] Fig.11 is a photograph of a colony of iPS cells according to Example 3.
[0160] [ Fig.12 ] Fig.12 is a photograph of a colony of iPS cells according to Example 3.
[0161] [ Fig.13 ] Fig.13 is a photograph of iPS cells according to Example 4.
[0162] [ Fig.14 ] Fig.14 is a graph showing the number of colonies of iPS cells according to Example 4.
[0163] [ Fig.15 ] Fig.15 is a photograph of a colony of iPS cells according to Example 4.
[0164] [ Fig.16 ] Fig.16 is a photograph of a colony of iPS cells according to Example 5.
[0165] [ Fig.17 ] Fig.17 is a graph showing the colony formation rate at each density of iPS cells according to Example 5.
[0166] [ Fig.18 ] Fig.18 is a graph showing the colony formation rate for each medium amount according to Example 5.
[0167] [ Fig.19 ] Fig.19 is a photograph of iPS cells according to Example 6.
[0168] [ Fig. 20 ] Fig. 20is a graph showing the number of colonies of iPS cells according to Example 6.
[0169] [ Fig.21 ] Fig.21 is a photograph of a colony of iPS cells according to Example 7.
[0170] [ Fig. 22 ] Fig. 22 is a graph showing the number of iPS cell colonies under various culture conditions according to Example 7.
[0171] [ Fig.23 ] Fig.23 are photographs of colonies of iPS cells according to each culture medium of Example 7.
[0172] [ Fig.24 ] Fig.24 is a diagram showing the differentiation state of the iPS cell colony according to Example 7.
[0173] [ Fig.25 ] Fig.25 is a photograph of iPS cells according to Example 8.
[0174] [ Fig.26 ] Fig.26 is a graph showing the colony formation rate for each medium amount according to Example 8.
[0175] [ Fig. 27 ] Fig. 27 is a photograph of the gel culture medium according to Example 9.
[0176] [ Fig.28 ] Fig.28 is a photograph of a colony of iPS cells according to Example 9.
[0177] [ Fig.29 ] Fig.29 is a photograph of a colony of iPS cells according to Example 10.
[0178] [ Fig.30 ] Fig.30 is a photograph of a colony of iPS cells according to Example 11.
[0179] [ Fig.31 ] Fig.31 is a photograph of a colony of iPS cells according to Example 12.
[0180] [ Fig.32 ] Fig.32 is a graph showing the size of the iPS cell colony according to Example 12.
[0181] [ Fig.33 ] Fig.33is a photograph of a colony of iPS cells according to Example 12.
[0182] [ Fig.34 ] Fig.34 is a diagram showing the differentiation state of the iPS cell colony according to Example 12.
[0183] [ Fig.35 ] Fig.35 This is a fluorescence microscope photograph according to Example 13.
[0184] [ Fig.36 ] Fig.36 is a diagram showing the analysis results using fluorescence-activated flow cytometry according to Example 13.
[0185] [ Fig.37 ] Fig.37 is a photograph of cells according to Example 14.
[0186] [ Fig.38 ] Fig.38 is a photograph of cells according to Example 14.
[0187] [ Fig.39 ] Fig.39 is a graph showing the percentage of transfection efficiency and survival rate according to Example 14.
[0188] [ Fig.40 ] Fig.40 is a photograph of cells according to Example 15.
[0189] [ Fig.41 ] Fig.41 These are photos of cells observed under a fluorescence microscope according to Example 15.
[0190] [ Fig.42 ] Fig.42 is a graph showing the percentage of TUJ-1 positive cells according to Example 15.
[0191] [ Fig.43 ] Fig.43 Photographs of cells according to Example 15 are shown.
[0192] [ Fig.44 ] Fig.44 is a schematic diagram of the transfection method according to Example 16.
[0193] [ Fig.45 ] Fig.45 is a photograph of cells according to Example 16.
[0194] [ Fig.46 ] Fig.46 Photographs of cells according to Example 16 are shown. DETAILED DESCRIPTION
[0195] Hereinafter, embodiments of the present invention will be described. In the following description of the accompanying drawings, the same or similar reference numerals will be used to refer to the same or similar parts. However, the accompanying drawings are schematic. Therefore, specific dimensions, etc. should be judged based on the following description. In addition, it should be understood that the relationship or ratio of the dimensions between the accompanying drawings may be different.
[0196] (First embodiment)
[0197] like Figure 1 As shown, the stem cell manufacturing system according to the first embodiment of the present invention includes: a separation device 10, which separates cells from blood; a pre-transfer cell solution sending channel 20, through which a solution containing cells separated by the separation device 10 flows; an inducer solution sending mechanism 21, which sends a pluripotency inducer into the pre-transfer cell solution sending channel 20; an inducer transfer device 30, which is connected to the pre-transfer cell solution transmission channel 20 and transfers the pluripotency inducer into cells to produce cells carrying the inducer; a cell cluster production device 40, which cultures cells carrying the inducer to produce a plurality of cell clusters composed of stem cells; and a packaging device 100, which sequentially packages a plurality of cell clusters.
[0198] The stem cell manufacturing system further includes a container 200 accommodating the separation device 10 , the pre-transfer cell solution sending channel 20 , the inducer solution sending mechanism 21 , the inducer transferring device 30 , the cell cluster producing device 40 and the packaging device 100 .
[0199] The stem cell manufacturing system may further include: an air purification device for purifying the gas in the container 200; a temperature control device for controlling the temperature of the gas in the container 200; and a carbon dioxide concentration control device for controlling the carbon dioxide (CO2) concentration of the gas in the container 200. 2 ) concentration. The air purification device may include a cleanliness sensor that monitors the cleanliness of the gas in the container 200. The air purification device uses, for example, a HEPA (High Efficiency Particulate Air) filter to purify the air in the container 200. According to, for example, ISO standard 14644-1, the air purification device maintains the cleanliness of the air in the container 200 at a cleanliness between ISO 1 and ISO 6. The temperature control device may include a temperature sensor that monitors the temperature of the gas in the container 200. CO 2 The concentration control device may include monitoring the CO concentration of the gas in the container 200. 2 Concentration of CO 2 Concentration sensor.
[0200] The container 200 is provided with, for example, a door. In a state where the door is closed, the interior is completely sealed so that the cleanliness, temperature and CO of the internal air are controlled. 2The concentration can be kept constant. The container 200 is preferably transparent so that the internal state of the device can be observed from the outside. The container 200 may be a glove box integrally including gloves such as rubber gloves.
[0201] The separation device 10 receives, for example, a vial containing human blood. The separation device 10 includes, for example, an anticoagulant tank storing an anticoagulant such as ethylenediaminetetraacetic acid (EDTA), heparin, and citrate dextrose formula A solution (ACD-A solution, Terumo Co., Ltd.). The separation device 10 adds the anticoagulant from the anticoagulant tank to the human blood using a pump or the like.
[0202] The separation device 10 includes, for example, a separation reagent tank that stores a monocyte separation reagent such as Ficoll-Paque PREMIUM (GE Healthcare Japan Co., Ltd.). The separation device 10 dispenses the monocyte separation reagent from the separation reagent tank at 5 mL / tube to, for example, two 15 mL tubes using a pump, etc. Note that a resin bag may be used instead of the tube.
[0203] The separation device 10 also includes a buffer solution tank storing a buffer solution such as phosphate buffered saline (PBS). The separation device 10 dilutes, for example, 5 mL of human blood by adding 5 mL of buffer obtained from the buffer tank using a pump, etc. In addition, the separation device 10 adds 5 mL of diluted human blood to the monocyte separation reagent in each tube using a pump, etc.
[0204] The separation device 10 also includes a centrifuge in which the temperature can be set. The centrifuge temperature is set to, for example, 18° C. The separation device 10 places each tube containing a reagent for separating monocytes and human blood, etc., in a holder of the centrifuge using a transport device, etc. The centrifuge centrifuges the solution in the tube at, for example, 400×g for 30 minutes. Instead of the tube, a resin bag may be centrifuged.
[0205] After centrifugation, the separation device 10 recovers the turbid middle layer composed of mononuclear cells in the solution in the tube using a pump or the like. The separation device 10 sends the recovered mononuclear cell suspension to the pre-transfer cell solution sending channel 20 using a pump or the like. Alternatively, the separation device 10 further adds, for example, 12 mL of PBS to, for example, 2 mL of the recovered mononuclear cell solution, and places the tube in a holder of a centrifuge. The centrifuge centrifuges the solution in the tube at, for example, 200×g for 10 minutes.
[0206] After centrifugation, the separation device 10 uses a pump or the like to aspirate the supernatant of the solution in the tube, and by adding 3 mL of a monocyte culture medium such as X-VIVO10 (R) (Lonza Japan Co., Ltd.), the monocyte solution is suspended in the tube. The separation device 10 uses a pump or the like to send the monocyte suspension to the pre-transfer cell solution sending channel 20. The separation device 10 can use a dialysis membrane to separate monocytes from blood. Alternatively, in the case of using somatic cells such as fibroblasts separated in advance from skin or the like, the separation device 10 may be unnecessary.
[0207] The separation device 10 can separate cells suitable for induction by methods other than centrifugal separation. When the cells to be separated are, for example, T cells, cells positive for any one of CD3, CD4, and CD8 can be separated by panning. When the cells to be separated are endothelial progenitor cells, cells positive for CD34 can be separated by panning. When the cells to be separated are B cells, cells positive for any one of CD10, CD19, and CD20 can be separated by panning. The separation method is not limited to panning, and cells can be separated by magnetic cell separation methods, flow cytometry, or other methods. Alternatively, the separation device 10 can separate cells suitable for induction by the method described in the embodiments mentioned later. For example, as described in the fifth embodiment, a magnetic separation device can be used to separate cells suitable for induction based on cell surface markers. Alternatively, a filter can be used to separate cells suitable for induction. The cells to be induced are not limited to blood cells, but can be fibroblasts, etc.
[0208] The inducer solution sending mechanism 21 includes an inducer transfer reagent tank for storing an inducer transfer reagent solution, etc. The inducer transfer reagent solution, such as a gene transfer reagent solution, contains, for example, an electroporation solution such as a human T cell Nucleofector (R) (Lonza Japan Co., Ltd.) solution, a supplement solution, and a plasmid group. The plasmid group contains, for example, 0.83μg of pCXLE-hOCT3 / 4-shp53-F, 0.83μg of pCXLE-hSK, 0.83μg of pCE-hUL, and 0.5μg of pCXWB-EBNA1. Alternatively, the inducer transfer reagent solution may contain the reagents described in the fourth and fifth embodiments mentioned later, etc. For example, as described in the fifth embodiment, RNA encoding reprogramming factors can be transferred to cells by lipid transfection. The inducer solution sending mechanism 21 uses a micropump, etc. to send the inducer transfer reagent solution into the pre-transfer cell solution sending channel 20, so that the mononuclear cell suspension is suspended in the inducer transfer reagent solution.
[0209] The inner wall of the pre-transfer cell solution sending channel 20 may be non-adhesive to cells by coating with poly-HEMA (poly-2-hydroxyethyl methacrylate) to prevent cells from adhering to the inner wall. Alternatively, a material that resists cell adhesion may be used as the material of the pre-transfer cell solution sending channel 20. In addition, CO having high thermometric conductivity may be used as the material of the pre-transfer cell solution sending channel 20. 2 A permeable material may be used as the material of the pre-transfer cell solution sending channel 20 so that the internal conditions of the pre-transfer cell solution sending channel 20 are equivalent to the controlled temperature and CO in the container 200. 2 From the viewpoint of preventing contamination, the pre-transfer cell solution sending channel 20 may also be provided with a backflow prevention valve.
[0210] The inducer transfer device 30 connected to the pre-transfer cell solution sending channel 20 is, for example, an electroporator, which receives a mixed solution of an inducer transfer reagent solution and a monocyte suspension and performs electroporation of monocytes with a plasmid. After electroporation, the inducer transfer device 30 adds a monocyte culture medium to a solution containing monocytes electroporated with a plasmid. The inducer transfer device 30 uses a pump or the like to send a solution containing monocytes electroporated with a plasmid (hereinafter referred to as "cells carrying inducers") into the post-transfer cell solution sending channel 31. Note that the inducer transfer device 30 is not limited to an electroporator. The inducer transfer device 30 can transfer the inducer to the cell by the method described in the fourth and fifth embodiments mentioned later. The culture medium can be a gel culture medium. In this case, the gel culture medium can, for example, not contain a growth factor such as basic fibroblast growth factor (bFGF). Alternatively, the gel culture medium can contain a low concentration of a growth factor such as bFGF of 400 μg / L or less, 40 μg / L or less, or 10 μg / L or less. The gel culture medium may contain no TGF-β, or may contain TGF-β at a low concentration of 600 ng / L or less, 300 ng / L or less, or 100 ng / L or less.
[0211] The inner wall of the post-transfer cell solution sending channel 31 can be kept non-adhesive by coating poly-HEMA to prevent cells from adhering to the inner wall. Alternatively, a material that resists cell adhesion can be used as the material of the post-transfer cell solution sending channel 31. In addition, CO having high thermometric conductivity 2 A permeable material may be used as the material of the post-transfer cell solution sending channel 31 so that the internal conditions of the post-transfer cell solution sending channel 31 are equivalent to the controlled temperature and CO in the container 200. 2 concentration. From the viewpoint of preventing contamination, the post-transfer cell solution sending channel 31 may also be provided with a backflow prevention valve. After electroporation, many cells die, and dead cells may form cell clusters. Therefore, the post-transfer cell solution sending channel 31 may be provided with a filter for removing dead cell clusters. Alternatively, Figure 2As shown, one or more walls with intermittently changing inner diameters may be provided inside the post-transfer cell solution delivery channel 31. Alternatively, as Figure 3 As shown, the inner diameter of the post-transferred cell solution sending channel 31 can be intermittently changed.
[0212] The cell cluster production device 40 connected to the post-transfer cell solution sending channel 31 includes: a reprogramming culture device 50, which cultures cells carrying the inducer produced by the inducer transfer device 30; a first segmentation mechanism 60, which segments the cell cluster composed of stem cells established by the reprogramming culture device 50 into multiple cell clusters; an expansion culture device 70, which amplifies and cultures the multiple cell clusters segmented by the first segmentation mechanism 60; a second segmentation mechanism 80, which segments the cell cluster composed of stem cells amplified and cultured by the expansion culture device 70 into multiple cell clusters; and a cell cluster conveying mechanism 90, which sequentially delivers the multiple cell clusters into the packaging device 100.
[0213] The reprogramming culture device 50 can accommodate a well plate therein. The reprogramming culture device 50 also includes a pipette. The reprogramming culture device 50 receives a solution containing cells carrying an inducer from the cell solution sending channel 31 after the transfer, and distributes the solution to the well by the pipette. The reprogramming culture device 50 adds a stem cell culture medium, such as StemFit (R) (Ajinomoto Co., Ltd.) after distributing the cells carrying the inducer to the wells for example for three days, five days and seven days. Basic fibroblast growth factor (basic FGF) can be added as a supplement to the culture medium. Note that sustained release beads such as Stem Beads FGF2 (Funakoshi Co., Ltd.) that continuously supply FGF-2 (basic FGF, bFGF or FGF-b) can be added to the culture medium. Because FGF is sometimes unstable, FGF can be stabilized by coupling a heparin-mimicking polymer to FGF. The reprogramming culture device 50 also replaces the culture medium, for example, after distributing the cells carrying the inducer to the wells for 9 days, and replaces the culture medium every two days thereafter until the cell clusters (colonies) of the iPS cells exceed 1 mm.
[0214] After forming the cell clusters, the reprogramming culture device 50 recovers the cell clusters by a pipette and adds a recombinant enzyme such as TrypLE Select(R) (Life Technologies, Inc.) as a substitute for trypsin to the recovered cell clusters. The reprogramming culture device 50 also places the container containing the recovered cell clusters in an incubator, where the cell clusters and the recombinant enzyme as a substitute for trypsin are incubated at 37°C in a 5% CO atmosphere. 2Alternatively, the reprogramming culture device 50 can destroy the cell clusters by pipetting using a pipette. As another alternative, the reprogramming culture device 50 can destroy the cell clusters by passing the cell clusters through a tube provided with a filter or a tube with an intermittently changing inner diameter, as in Figure 2 or Figure 3 The cell solution after transfer is shown to be sent to channel 31. Then, the reprogramming culture device 50 adds a culture medium for pluripotent stem cells, such as StemFit(R) (Ajinomoto Co., Ltd.), to the solution containing the disrupted cell clusters.
[0215] The culture in the reprogramming culture device 50 can be carried out under CO 2 The culture may be carried out in a permeable bag rather than a well plate. The culture may be an adherent culture, or may be a floating culture. In the case of a floating culture, the culture may be stirred. The culture medium may be in agar form. Examples of agar-form culture mediums include gellan gum polymers. When an agar-form culture medium is used, even in the form of a floating culture, stirring is not required and it is possible to produce single cell clusters derived from one cell because the cells neither sink nor adhere. The culture in the reprogramming culture device 50 may be a hanging drop culture.
[0216] The reprogramming culture device 50 may include a first culture medium supply device, which supplies a first culture medium to the well plate or CO. 2 The permeable bag can be used to replenish the culture medium. The first culture medium replenishment device can recover the orifice plate or CO 2 The culture solution in the permeable bag is filtered using a filter or a dialysis membrane, and the purified culture solution is circulated. In this case, growth factors and the like can be added to the culture solution to be circulated. The reprogramming culture device 50 may also include, for example, a temperature control device for controlling the temperature of the culture solution and a humidity control device for controlling the humidity near the culture solution.
[0217] In the reprogramming culture device 50, for example, Figure 4 As shown, the cells can be placed in a culture fluid permeable bag 301 such as a dialysis membrane, and the culture fluid permeable bag 301 can be placed in a culture fluid impermeable and CO 2The permeable bag 302 is provided, and the culture solution can be placed in the bags 301 and 302. A plurality of bags 302 containing fresh culture solution can be prepared, and the reprogramming culture device 50 can replace the bag 302 containing the bag 301 containing cells with another bag 302 containing fresh culture solution at a predetermined time interval. Note that the culture method in the reprogramming culture device 50 is not limited to the above method, and the culture can be carried out by the method described in the second and third embodiments mentioned later. For example, as described in the second embodiment, a gel culture medium can be used. In this case, the gel culture medium may, for example, not contain growth factors such as basic fibroblast growth factor (bFGF). Alternatively, the gel culture medium may contain a low concentration of growth factors such as bFGF of 400 μg / L or less, 40 μg / L or less, or 10 μg / L or less. The gel culture medium may not contain tgf-β, or may contain a low concentration of tgf-β of 600 ng / L or less, 300 ng / L or less, or 100 ng / L or less. As described in the third embodiment, a floating culture container may be used, comprising: a dialysis tube containing stem cells and a gel medium; and a container containing the dialysis tube, wherein the gel medium is placed around the dialysis tube.
[0218] The stem cell manufacturing system may further include a reprogramming culture photography device for photographing the culture in the reprogramming culture device 50. Note that when a colorless culture solution is used as the culture solution for the reprogramming culture device 50, it is possible to suppress diffuse reflection or autofluorescence that may occur when a colored culture solution is used. Because induced cells and uninduced cells differ in terms of cell shape and size, the stem cell manufacturing system may further include an induction state monitoring device that calculates the percentage of induced cells by photographing the cells in the reprogramming culture device 50. Alternatively, the induction state monitoring device may identify the percentage of induced cells by an antibody immunostaining method or an RNA extraction method. The stem cell manufacturing system may further include an uninduced cell removal device that removes uninduced cells by a magnetic cell separation method, flow cytometry, or the like.
[0219] The first cell cluster solution sending channel 51 is connected to the reprogramming culture device 50. The reprogramming culture device 50 sends a solution containing a recombinant enzyme as a substitute for trypsin and a cell cluster into the first cell cluster solution sending channel 51 using a pump or the like. When the cell clusters can be physically destroyed, the recombinant enzyme as a substitute for trypsin may be unnecessary. The first cell cluster solution sending channel 51 may be connected to a branch channel having an inner diameter that allows only induced cells having a size smaller than a predetermined size to pass through and removes uninduced cells having a predetermined size or larger.
[0220] The inner wall of the first cell cluster solution delivery channel 51 may be coated with polyHEMA to prevent the cells from adhering to the inner wall. Alternatively, a material that resists cell adhesion may be used as the material of the first cell cluster solution delivery channel 51. In addition, a CO having high thermometric conductivity may be used. 2 A permeable material may be used as the material of the first cell cluster solution sending channel 51 so that the internal conditions of the first cell cluster solution sending channel 51 are equivalent to the controlled temperature and CO in the container 200. 2 From the viewpoint of preventing contamination, the first cell cluster solution sending channel 51 may also be provided with a backflow prevention valve.
[0221] The first cell cluster solution sending channel 51 is connected to the first segmentation mechanism 60. The first segmentation mechanism 60 includes, for example, a grid. When passing through the grid by hydraulic pressure, the cell clusters contained in the solution are segmented into multiple cell clusters corresponding to the size of each pore of the grid. For example, when the grid has pores of uniform size, the sizes of the multiple cell clusters segmented are also almost uniform. Alternatively, the first segmentation mechanism 60 may include a nozzle. For example, the interior of the generally conical nozzle is microfabricated in a stepped form. When flowing through the nozzle, the cell clusters contained in the solution are segmented into multiple cell clusters. The amplification culture device 70 is connected to the first segmentation mechanism 60. The solution containing the cell clusters segmented by the first segmentation mechanism 60 is sent to the amplification culture device 70.
[0222] The expansion culture device 70 can accommodate a well plate therein. The expansion culture device 70 also includes a pipette. The expansion culture device 70 receives a solution containing a plurality of cell clusters from the first segmentation mechanism 60 and distributes the solution into the wells by the pipette. After distributing the cell clusters into the wells, the expansion culture device 70 is heated, for example, at 5% CO. 2 The cell clusters are cultured at 37° C. for about eight days in an environment. The culture medium of the expansion culture device 70 is replaced as needed.
[0223] Then, the expansion culture device 70 adds a recombinant enzyme as a substitute for trypsin, such as TrypLE Select(R) (Life Technologies, Inc.), to the cell clusters. The expansion culture device 70 also places the container containing the cell clusters in an incubator, where the cell clusters and the recombinant enzyme as a substitute for trypsin are incubated at 37° C. under 5% CO. 2 The cell clusters are reacted in the environment for 1 minute. Then, the expansion culture device 70 adds a culture medium, such as a maintenance culture medium, to the solution containing the cell clusters. The expansion culture device 70 also uses an automatic cell scraper or the like to separate the cell clusters from the container, and sends the solution containing the cell clusters to the first dividing mechanism 60 via the expansion culture liquid sending channel 71.
[0224] The culture in the expansion culture device 70 can be carried out under CO 2The culture may be carried out in a permeable bag rather than a well plate. The culture may be an adherent culture, or may be a floating culture. Alternatively, the culture may be a hanging drop culture. In the case of a floating culture, the culture may be stirred. The culture medium may be in agar form. Examples of agar-form culture mediums include gellan gum polymers. When an agar-form culture medium is used, stirring is not required, even in the form of a floating culture, because the cells neither sink nor adhere.
[0225] The expansion culture device 70 may include a second culture medium supply device, which supplies the culture medium to the well plate or CO. 2 The permeable bag can be used to replenish the culture medium. The second culture medium replenishment device can recover the well plate or CO 2 The culture fluid in the permeable bag is filtered using a filter or a dialysis membrane, and the purified culture fluid is circulated. In this case, growth factors and the like can be added to the culture fluid to be circulated. The expansion culture device 70 may also include, for example, a temperature control device for controlling the temperature of the culture fluid and a humidity control device for controlling the humidity near the culture fluid.
[0226] In addition, in the expansion culture device 70, for example, Figure 4 As shown, the cells can be placed in a culture fluid permeable bag 301 such as a dialysis membrane, and the culture fluid permeable bag 301 can be placed in a culture fluid impermeable and CO 2 The cells are placed in the permeable bag 302, and the culture solution can be placed in the bags 301 and 302. A plurality of bags 302 containing fresh culture solution can be prepared, and the expansion culture device 70 replaces the bag 302 in which the bag 301 containing the cells is placed with another bag 302 containing fresh culture solution at a predetermined time interval. The culture method in the expansion culture device 70 is not limited to the above method, and the culture can be performed by the methods described in the second and third embodiments mentioned later.
[0227] The stem cell manufacturing system may further include an expansion culture photography device for photographing the culture in the expansion culture device 70. Note that when a colorless culture solution is used as the culture solution used in the expansion culture device 70, it is possible to suppress diffuse reflection or autofluorescence that may occur when a colored culture solution is used. Because induced cells and uninduced cells differ in terms of cell shape and size, etc., the stem cell manufacturing system may further include an induction state monitoring device that calculates the percentage of induced cells by photographing the cells in the expansion culture device 70. Alternatively, the induction state monitoring device may identify the percentage of induced cells by an antibody immunostaining method or an RNA extraction method. The stem cell manufacturing system may further include an uninduced cell removal device that removes uninduced cells by a magnetic cell separation method, flow cytometry, etc.
[0228] The cell clusters divided by the first dividing mechanism 60 are cultured again in the expansion culture device 70. The division of the cell clusters in the first dividing mechanism 60 and the culturing of the cell clusters in the expansion culture device 70 are repeated until a desired amount of cells is obtained.
[0229] The second cell cluster solution sending channel 72 is connected to the expansion culture device 70. The expansion culture device 70 sends a solution containing the cell clusters after expansion culture separated from the container into the second cell cluster solution sending channel 72 using a pump or the like. The second cell cluster solution sending channel 72 may be connected to a branch channel having an inner diameter that allows only induced cells having a size smaller than a predetermined size to pass therethrough and removes uninduced cells having a predetermined size or larger.
[0230] The inner wall of the second cell cluster solution delivery channel 72 may be coated with polyHEMA to prevent the cells from adhering to the inner wall. Alternatively, a material that resists cell adhesion may be used as the material of the second cell cluster solution delivery channel 72. In addition, a CO having high thermometric conductivity may be used. 2 A permeable material may be used as the material of the second cell cluster solution sending passage 72 so that the internal conditions of the second cell cluster solution sending passage 72 are equivalent to the controlled temperature and CO in the container 200. 2 From the viewpoint of preventing contamination, the second cell cluster solution sending channel 72 may also be provided with a backflow prevention valve.
[0231] The second cell cluster solution sending channel 72 is connected to the second segmentation mechanism 80. The second segmentation mechanism 80 includes, for example, a grid. When the grid is passed through by hydraulic pressure, the cell clusters contained in the solution are segmented into a plurality of cell clusters corresponding to the size of each pore of the grid. For example, when the grid has pores of uniform size, the sizes of the plurality of segmented cell clusters are also almost uniform. Alternatively, the second segmentation mechanism 80 may include a nozzle. For example, the interior of a generally conical nozzle is microfabricated in a stepped form. When flowing through the nozzle, the cell clusters contained in the solution are segmented into a plurality of cell clusters.
[0232] The cell cluster transport mechanism 90 that sequentially transports a plurality of cell clusters to the packaging device 100 is connected to the second segmenting mechanism 80. A pre-packaged cell channel 91 is connected between the cell cluster transport mechanism 90 and the packaging device 100. The cell cluster transport mechanism 90 sequentially transports the cell clusters segmented by the second segmenting mechanism 80 to the packaging device 100 via the pre-packaged cell channel 91 using a pump or the like.
[0233] The pre-packaged cell channel 91 may be coated with poly-HEMA to prevent cells from adhering thereto. Alternatively, a material that resists cell adhesion may be used as the material for the pre-packaged cell channel 91. In addition, CO having high thermometric conductivity 2The permeable material can be used as the material of the pre-packaged cell channel 91, so that the internal conditions of the pre-packaged cell channel 91 are equivalent to the controlled temperature and CO in the container 200. 2 From the viewpoint of preventing contamination, the prepackaged cell channel 91 may also be provided with a backflow prevention valve.
[0234] The cryopreservation solution delivery mechanism 110 is connected to the pre-packaged cell channel 91. The cryopreservation solution delivery mechanism 110 delivers the cell cryopreservation solution to the pre-packaged cell channel 91. Therefore, the cell cluster is suspended in the cell cryopreservation solution in the pre-packaged cell channel 91.
[0235] The packaging device 100 sequentially freezes multiple cell clusters sent via the pre-packaged cell channel 91. For example, each time a cell cluster is received, the packaging device 100 places the cell cluster in a CryoTube and immediately freezes the cell cluster solution, for example at -80°C or lower. If a CryoTube with a smaller surface area per unit volume is used, freezing is often time-consuming. Therefore, it is preferred to use a CryoTube with a larger surface area per unit volume. It is possible to increase the survival rate of cells after thawing by using a CryoTube with a larger surface area per unit volume. Examples of the shape of CryoTube include, but are not limited to, capillaries and spheres. Depending on the desired survival rate of cells after thawing, flash freezing is not necessary.
[0236] For example, a vitrification method is used in freezing. In this case, DAP213 (Cosmo Bio Co., Ltd.) or freezing culture medium (ReproCELL Co., Ltd.) can be used as a cell cryopreservation solution. Freezing can be performed by conventional methods other than the vitrification method. In this case, CryoDefend-Stem Cell (R&D Systems Co., Ltd.), STEM-CELLBANKER (R) (Nippon Zenyaku Kogyo Co., Ltd.), etc. can be used as a cell cryopreservation solution. Freezing can be performed using liquid nitrogen, or a Peltier device can be used. By using a Peltier device, it is possible to regulate temperature changes and suppress temperature changes. The packaging device 100 outputs the CryoTube to the outside of the container 200. In the case of clinical use of frozen cells, the CryoTube is preferably a completely sealed system. However, the packaging device 100 can package stem cells in the CryoTube without freezing the stem cells.
[0237] The stem cell manufacturing system may further include a packaging step photographing device for photographing the packaging step in the packaging device 100 .
[0238] The stem cell manufacturing system may further include a sterilizing device for sterilizing the interior of the container 200. The sterilizing device may be a dry heat sterilizing device. Note that the circuits of the electrical devices such as the separation device 10, the pre-transfer cell solution delivery channel 20, the inducer solution delivery mechanism 21, the inducer transfer device 30, the cell cluster production device 40, and the packaging device 100 are preferably heat-resistant circuits. Alternatively, the sterilizing device may sterilize the interior of the container 200 by blowing sterilizing gas such as ozone gas, hydrogen peroxide gas, formalin gas, etc. into the container 200.
[0239] The stem cell manufacturing system can transmit the operation records of the separation device 10, the pre-transfer cell solution delivery channel 20, the inducer solution delivery mechanism 21, the inducer transfer device 30, the cell cluster production device 40 and the packaging device 100 and the images taken by the photographic device to the external server by wired or wireless means. The external server can use a neural network to analyze, for example, the connection between conditions (e.g., inducer transfer conditions, culture conditions and freezing conditions) and results (e.g., incomplete reprogramming of stem cells, failure of stem cell differentiation and proliferation, and chromosome aberrations) to extract the conditions leading to the results or predict the results. The external server can also regulate the separation device 10, the inducer solution delivery mechanism 21, the inducer transfer device 30, the cell cluster production device 40 and the packaging device 100 in the stem cell manufacturing system based on the standard operating procedure (SOP), monitor whether each device is operated based on the SOP, and automatically make the operation records of each device.
[0240] The above-mentioned stem cell production system has the potential to fully automatically achieve the induction, establishment, expansion culture and cryopreservation of stem cells such as iPS cells at one time.
[0241] (Other embodiments)
[0242] For example, the inducer transfer device 30 can induce cells by RNA transfection, rather than by electroporation. Alternatively, cells can be induced by viral (for example, retrovirus, slow virus and Sendai virus) vector or plasmid. Before the transfer, the cell solution sending channel 20, the cell solution sending channel 31 after the transfer, the cell cluster solution sending channel 51, the extended culture fluid sending channel 71, the cell cluster solution sending channel 72 and the pre-packaged cell channel 91 can be arranged on the substrate by microfluidic technology. The device that inducer ribonucleic acid (RNA) is transferred to the induced stem cell by lipofection to differentiate stem cells into somatic cells can be connected to the stem cell manufacturing system. For example, the method described in the sixth embodiment described later can be used as the method that inducer ribonucleic acid (RNA) is transferred to the induced stem cell by lipofection to differentiate stem cells into somatic cells. Somatic cells can be, for example, neuronal cells.
[0243] (Second embodiment)
[0244] The floating culture method for stem cells according to the second embodiment of the present invention includes floating culture of stem cells in a gel culture medium. The stem cells are, for example, induced pluripotent stem (iPS) cells or embryonic stem cells (ES cells). The gel culture medium is not stirred. The gel culture medium does not contain feeder cells. The stem cells proliferate in the gel culture medium while maintaining their undifferentiated state.
[0245] For example, before floating culture, stem cells are dissociated into single cells, and the stem cells dissociated into single cells are placed in a gel medium. The single cells proliferate while maintaining their clonality to form colonies in the gel medium.
[0246] The gel medium is prepared, for example, by adding deacetylated gellan gum to a medium for stem cells at a final concentration of 0.5% to 0.001% by weight, 0.1% to 0.005% by weight, or 0.05% to 0.01% by weight.
[0247] The gel culture medium may contain at least one polymer compound selected from the group consisting of gellan gum, hyaluronic acid, rhamnose gum, diutan gum, xanthan gum, carrageenan, fucoidan, pectin, pectic acid, pectinic acid, heparan sulfate, heparin, heparan sulfate, keratan sulfate, chondroitin sulfate, dermatan sulfate, rhamnose sulfate and salts thereof. The gel culture medium may contain methylcellulose. The methylcellulose contained therein inhibits aggregation between cells.
[0248] Alternatively, the gel culture medium may contain at least one thermosensitive gel selected from the group consisting of poly(glycerol monomethacrylate) (PGMA), poly(2-hydroxypropyl methacrylate) (PHPMA), poly(N-isopropylacrylamide) (PNIPAM), amine-terminated, carboxylic acid-terminated, maleimide-terminated, N-hydroxysuccinimide (NHS) ester-terminated, triethoxysilane-terminated, poly(N-isopropylacrylamide-co-acrylamide), poly(N-isopropylacrylamide-co-acrylic acid), poly(N-isopropylacrylamide-co-butyl acrylate), poly(N-isopropylacrylamide-co-methacrylic acid), poly(N-isopropylacrylamide-co-methacrylic acid-co-octadecyl acrylate) and N-isopropylacrylamide.
[0249] A human ES / iPS culture medium, such as Primate ES cell culture medium (ReproCELL Co., Ltd.) can be used as a culture medium for stem cells.
[0250] However, the culture medium for stem cells is not limited thereto, and various stem cell culture media can be used. For example, Primate ES cell culture medium, Reprostem, ReproFF, ReproFF2, ReproXF (ReproCELL Co., Ltd.), mTeSR1, TeSR2, TeSRE8, ReproTeSR (STEMCELL Technologies Co., Ltd.), PluriSTEM (R) human ES / iPS culture medium (Merck KGaA), NutriStem (R) XF / FF culture medium for human iPS and ES cells, Pluriton reprogramming culture medium (Stemgent Co., Ltd.), PluriSTEM (R), StemFit AK02N, StemFit AK03 (Ajinomoto Co., Ltd.), serum-free and feeder cell culture medium ESC-Sure (R) (Applied StemCell Co., Ltd.) and L7 (R) hPSC culture system (Lonza Japan Co., Ltd.) can be used.
[0251] For example, a ROCK inhibitor is added to the gel medium at a final concentration of 1000 μmol / L or more and 0.1 μmol / L or less, 100 μmol / L or more and 1 μmol / L or less, or 5 μmol / L or more and 20 μmol / L or less every day. The ROCK inhibitor added to the gel medium promotes the formation of colonies by stem cells.
[0252] The gel culture medium may, for example, not contain growth factors such as basic fibroblast growth factor (bFGF). Alternatively, the gel culture medium may contain a low concentration of growth factors such as bFGF at a concentration of 400 μg / L or less, 40 μg / L or less, or 10 μg / L or less. Compared with gel culture medium containing a high concentration of growth factors such as bFGF, a gel culture medium without growth factors such as bFGF or a gel culture medium containing a low concentration of growth factors such as bFGF easily promotes colony formation of stem cells.
[0253] The gel medium may contain no TGF-β, or may contain TGF-β at a low concentration of 600 ng / L or less, 300 ng / L or less, or 100 ng / L or less.
[0254] The concentration of stem cells in the gel culture medium can be, for example, 2×10 5 cells / mL or higher, 2.25×10 5 cells / mL or higher, or 2.5×10 5cells / mL or higher. If the concentration of stem cells in the gel medium is less than 2×10 5 cells / mL, the colony formation rate tends to decrease.
[0255] The floating culture method for stem cells according to the second embodiment of the present invention is likely to form stem cell colonies from single cells. Although this method is a floating culture method, since the floating culture method of stem cells does not require stirring of the culture medium, the stem cells do not collide with each other. Therefore, it is possible to maintain the clonality of the colony. Therefore, when the stem cells are, for example, iPS cells, the clonality of the iPS cells derived from one somatic cell can be ensured. In addition, since the stem cells do not collide with each other, the stem cell colonies can maintain a uniform size. In addition, compared with the adherent culture method, the floating culture method can culture a large number of colonies in a small space. Note that it is possible to maintain a cultured stem cell cluster in the floating culture.
[0256] Since the discovery of ES / iPS cells, growth factors such as bFGF or Tgf-β have been considered essential for the culture of ES / iPS cells. However, growth factors such as bFGF are rapidly degraded under culture conditions of about 37°C. Therefore, it is necessary to replace the culture medium containing bFGF or Tgf-β with fresh culture medium containing bFGF or Tgf-β every day, or to add bFGF or Tgf-β etc. thereto every day. The bFGF used for culture is usually a recombinant protein. Clinical-grade recombinant proteins need to be produced according to very strict regulations.
[0257] When the concentration of bFGF is a low concentration of, for example, 10 ng / mL, it has been considered necessary to use mouse-derived fibroblasts as feeder cells. However, stem cells cultured using feeder cells derived from animals such as mice cannot be used for transplantation or regenerative medicine. This has always been a bottleneck in the clinical application of stem cells.
[0258] Although also developed feeder-free culture fluid that does not use feeder cells, feeder-free culture fluid generally contains bFGF of 25 times the amount contained in the culture fluid using feeder cells and contains bFGF of very high concentration, such as 100ng / mL. However, it is difficult to cultivate ES / iPS cells without karyotype abnormalities using feeder-free culture fluid containing high concentrations of bFGF. Therefore, many iPS cells are destroyed. ES / iPS cells cultivated in feeder-free culture fluid containing high concentrations of bFGF are often unlikely to differentiate into specific somatic cells. Therefore, feeder-free culture fluid partly causes the reduction of production efficiency of somatic cells necessary for stem cell transplantation.
[0259] In contrast, the floating culture method for stem cells according to the second embodiment of the present invention makes it possible to culture and proliferate stem cells without using feeder cells while maintaining their undifferentiated state. Even without using feeder cells, the floating culture method for stem cells according to the second embodiment of the present invention makes it possible to culture and proliferate stem cells without using growth factors such as bFGF or using low concentrations of growth factors such as bFGF while maintaining their undifferentiated state.
[0260] (Third Embodiment)
[0261] like Figure 5 As shown, a floating culture container for stem cells according to a third embodiment of the present invention comprises: a dialysis tube accommodating stem cells and a gel culture medium; and a container accommodating the dialysis tube, wherein the gel culture medium is placed around the dialysis tube.
[0262] Dialysis tubing is permeable to, for example, ROCK inhibitors. The molecular weight cut-off of dialysis tubing is 0.1 kDa or larger, 10 kDa or larger, or 50 kDa or larger. Dialysis tubing is made of, for example, cellulose ester, ethyl cellulose, cellulose ester derivatives, regenerated cellulose, polysulfone, polyacrylonitrile, polymethyl methacrylate, ethylene-vinyl alcohol copolymer, polyester-based polymer alloy, polycarbonate, polyamide, cellulose acetate, cellulose diacetate, cellulose triacetate, cuprammonium rayon, saponified cellulose, hemodialysis membrane, phosphatidylcholine membrane or vitamin E envelope. Conical tubes such as centrifuge tubes can be used as containers. Container is made of, for example, polypropylene.
[0263] The stem cells to be placed in the dialysis tube are the same as those in the second embodiment. Likewise, the gel culture medium to be placed in the dialysis tube is the same as that in the second embodiment. However, the gel culture medium to be placed in the dialysis tube may not contain a ROCK inhibitor. The gel culture medium to be placed around the dialysis tube in the container is the same as that in the second embodiment. The gel culture medium to be placed around the dialysis tube in the container contains a ROCK inhibitor.
[0264] During the floating culture of stem cells in the dialysis tube, the gel medium around the dialysis tube in the container is replaced or supplemented with fresh gel medium. However, replacing the gel medium in the dialysis tube may be unnecessary.
[0265] For conventional floating culture systems, it can be difficult to replace the culture medium without aspirating the cells. However, unless the culture medium is replaced with fresh culture medium, waste can accumulate. In addition, unless the culture medium is replaced or supplemented with fresh culture medium, the culture medium can lack culture medium components.
[0266] In contrast, by using a floating culture container for stem cells according to the third embodiment of the present invention, even if the culture medium around the dialysis tube is replaced with a fresh culture medium, it is possible to avoid sucking stem cells because the stem cells are in the dialysis tube. In addition, even when the culture medium around the dialysis tube is replaced with a fresh culture medium, the amount of the culture medium in the dialysis tube is difficult to change. Therefore, the density of the stem cells in the dialysis tube remains unchanged. High concentrations of waste in the dialysis tube move to the outside of the dialysis tube. Culture medium components move from the external culture medium of the dialysis tube into the dialysis tube, where the concentration of the culture medium components in the dialysis tube is reduced. Therefore, it is possible to keep the culture medium around the stem cells fresh.
[0267] (Fourth embodiment)
[0268] The method for inducing stem cells according to the fourth embodiment of the present invention includes inducing stem cells from somatic cells cultured in a floating gel medium. The somatic cells are, for example, fibroblasts. The stem cells are, for example, iPS cells. The gel medium is not stirred. The gel medium does not contain feeder cells.
[0269] The gel medium is prepared, for example, by adding deacetylated gellan gum to a medium for stem cells at a final concentration of 0.5% to 0.001% by weight, 0.1% to 0.005% by weight, or 0.05% to 0.01% by weight.
[0270] The gel culture medium may contain at least one polymer compound selected from the group consisting of gellan gum, hyaluronic acid, rhamnose gum, diutan gum, xanthan gum, carrageenan, fucoidan, pectin, pectic acid, pectinic acid, heparan sulfate, heparin, heparan sulfate, keratan sulfate, chondroitin sulfate, dermatan sulfate, rhamnose sulfate and salts thereof. The gel culture medium may contain methylcellulose. The methylcellulose contained therein inhibits aggregation between cells.
[0271] Alternatively, the gel culture medium may contain at least one thermosensitive gel selected from the group consisting of poly(glycerol monomethacrylate) (PGMA), poly(2-hydroxypropyl methacrylate) (PHPMA), poly(N-isopropylacrylamide) (PNIPAM), amine-terminated, carboxylic acid-terminated, maleimide-terminated, N-hydroxysuccinimide (NHS) ester-terminated, triethoxysilane-terminated, poly(N-isopropylacrylamide-co-acrylamide), poly(N-isopropylacrylamide-co-acrylic acid), poly(N-isopropylacrylamide-co-butyl acrylate), poly(N-isopropylacrylamide-co-methacrylic acid), poly(N-isopropylacrylamide-co-methacrylic acid-co-octadecyl acrylate) and N-isopropylacrylamide.
[0272] A human ES / iPS culture medium, such as Primate ES cell culture medium (ReproCELL Co., Ltd.) can be used as a culture medium for stem cells.
[0273] However, the culture medium for stem cells is not limited thereto, and various stem cell culture media can be used. For example, Primate ES cell culture medium, Reprostem, ReproFF, ReproFF2, ReproXF (ReproCELL Co., Ltd.), mTeSR1, TeSR2, TeSRE8, ReproTeSR (STEMCELL Technologies Co., Ltd.), PluriSTEM (R) people ES / iPS culture medium (Merck KGaA), NutriStem (R) XF / FF culture medium for human iPS and ES cells, Pluriton reprogramming culture medium (Stemgent Co., Ltd.), PluriSTEM (R), StemFit AK02N, StemFit AK03 (Ajinomoto Co., Ltd.), serum-free and feeder cell culture medium ESC-Sure (R) (Applied StemCell Co., Ltd.) and L7 (R) hPSC culture system (Lonza Japan Co., Ltd.) for hESC / iPS can be used. Gel culture medium is placed in, for example, a tube.
[0274] The gel medium may, for example, be free of growth factors such as basic fibroblast growth factor (bFGF). Alternatively, the gel medium may contain a low concentration of growth factors such as bFGF at a concentration of 400 μg / L or less, 40 μg / L or less, or 10 μg / L or less.
[0275] The gel medium may contain no TGF-β, or may contain TGF-β at a low concentration of 600 ng / L or less, 300 ng / L or less, or 100 ng / L or less.
[0276] (Example 1)
[0277] 500 mL of Primate ES cell culture medium (ReproCELL Co., Ltd.) and 0.2 mL of bFGF (Gibco PHG0266) at a concentration of 10 μg / mL were mixed to prepare a human iPS culture medium containing bFGF.
[0278] Deacetylated gellan gum (Nissan Chemical Industries, Ltd.) was added to the human iPS culture medium containing bFGF at a concentration of 0.02% by weight to prepare a human iPS gel culture medium containing bFGF. In addition, 5 mL of trypsin at a concentration of 2.5% by weight, 5 mL of collagenase IV at a concentration of 1 mg / mL, 0.5 mL of CaCl2 at a concentration of 0.1 mol / L, 10 mL of KnockOut Serum Replacement (R) (Invitrogen 10828-028) and 30 mL of purified water were mixed to prepare a dissociation solution generally referred to as CTK solution.
[0279] During the culture on feeder cells, 300 μL / well of CTK solution was added to a 6-well culture dish (Thermo Fisher Scientific 12-556-004) containing iPS cells, and the 6-well culture dish was incubated in CO. 2 Incubate in an incubator for 3 minutes. After three minutes, remove the culture dish from the incubator. After confirming that only the feeder cells have detached from the culture dish, remove the CTK solution with an aspirator. After removing the CTK solution, wash the iPS cells by adding PBS (Santa Cruz Biotech sc-362183) to the 6-well culture dish at 500 μL / well, and then remove the PBS from the 6-well culture dish. Add 0.3 mL / well of dissociation solution (Accutase(R)) to the 6-well culture dish, and then place it in a CO 2 The cells were incubated in an incubator for 5 minutes. Then, 0.7 mL / well of iPS medium containing bFGF was added to the 6-well culture dish to suspend the iPS cells until they became single cells.
[0280] After iPS cell suspension, 4 mL of human iPS culture medium containing bFGF was added to a 15 mL centrifuge tube, and the iPS cell suspension was centrifuged at 270 g using a centrifuge. After centrifugation, the supernatant was removed, and 1 mL of human iPS culture medium containing bFGF was added to the 15 mL centrifuge tube. The number of cells was counted using a hemocytometer. After cell counting, 5 × 10 5 iPS cells were seeded into a 15 mL Falcon tube (Corning 352096) or a non-adherent culture dish and then cultured in a floating state without stirring.
[0281] In a 15mL tube, 2mL of human iPS gel culture medium containing bFGF was used. In a non-adhesive culture dish, 2mL of human iPS culture medium containing bFGF and not containing gellan gum was used. ROCK inhibitor (Selleck Chemicals S1049) was added to each culture medium at 10μmol / L. Then, 500μL of human iPS gel culture medium containing bFGF was added to a 15mL tube and a non-adhesive culture dish every day, and 500μL of human iPS culture medium containing bFGF was added to a non-adhesive culture dish every day. In addition, ROCK inhibitor was added to a 15mL tube and a non-adhesive culture dish at a final concentration of 10μmol / L every day, and floating culture was continued for 7 days.
[0282] The results are as follows Figure 6 As shown. Figure 6 As shown in (b), when iPS cells were cultured in a non-adherent culture dish using a human iPS culture medium containing bFGF and without gellan gum, aggregation between iPS cell colonies was clearly observed. Figure 6 As shown in (a), when iPS cells were cultured in a 15 mL tube using human iPS gel medium containing bFGF, no obvious aggregation was observed. Figure 7 (a) is a photograph taken on the first day when iPS cells were cultured in a 15 mL tube using human iPS gel medium containing bFGF. Figure 7 (b) is a photograph taken on day 9 when iPS cells were cultured in a 15 mL tube using human iPS gel culture medium containing bFGF. Figure 7 (a) and Figure 7 (b) is a photograph confirming that iPS cells of different lines formed their own colonies without agglomerating with each other.
[0283] Figure 8 (a) is a photograph of an iPS cell colony that had been cultured floating in gel medium for 7 days, taken just before re-plating on feeder cells. Figure 8 (b) is a photo taken three days after the colonies were confirmed morphologically. Fig. 9 As shown, more than 95% of the colonies were confirmed to be undifferentiated. These results indicate that iPS cells can be cultured in gel culture medium while maintaining their undifferentiated state.
[0284] (Example 2)
[0285] The same human iPS culture medium containing bFGF and human iPS gel culture medium containing bFGF as in Example 1 were prepared. During the culture on the feeder cells, 300 μL / well of the CTK solution was added to the 6-well culture dish containing the iPS cells, and the 6-well culture dish was incubated in CO 2Incubate in the incubator for 3 minutes. After three minutes, remove the culture dish from the incubator. After confirming that only the feeder cells have detached from the culture dish, remove the CTK solution with an aspirator. After removing the CTK solution, wash the iPS cells by adding PBS to the culture dish at 500 μL / well, and then remove the PBS from the culture dish. Add Accumax at 0.3 mL / well to the culture dish, and then place it in a CO 2 The cells were incubated in an incubator for 5 minutes. Then, 0.7 mL / well of iPS medium containing bFGF was added to the culture dish to suspend the iPS cells until they became single cells.
[0286] After iPS cells were suspended, 4 mL of human iPS culture medium containing bFGF was added to a 15 mL centrifuge tube, and the iPS cell suspension was centrifuged at 270 g using a centrifuge. After centrifugation, the supernatant was removed, and 1 mL of human iPS culture medium containing bFGF was added to the 15 mL centrifuge tube. The number of cells was counted using a hemocytometer. After cell counting, 5 × 10 5 iPS cells were seeded into a 15 mL tube and then cultured in a floating manner without stirring.
[0287] In a 15 mL tube, 2 mL of human iPS gel culture medium containing bFGF was used. ROCK inhibitor was added to each culture medium at 10 μmol / L. Then, 500 μL of human iPS gel culture medium containing bFGF was added to the 15 mL tube every day. The gel culture medium (500 μL) contained 0.5 μL of ROCK inhibitor. As a control, iPS cells were floated and cultured for 7 days under the same conditions as above, except that ROCK inhibitor was not added.
[0288] like Fig.10 As shown in (a), when ROCK inhibitor was not added to the human iPS culture medium containing bFGF, iPS cells did not form colonies. Fig.10 As shown in (b), when ROCK inhibitor was added to human iPS culture medium containing bFGF, iPS cells formed colonies. These results indicate that ROCK inhibitor is effective for floating culture of iPS cells from single cells.
[0289] (Example 3)
[0290] A human iPS gel culture medium containing bFGF was prepared in the same manner as in Example 1. In addition, a human iPS culture medium without bFGF was prepared, which was the same as the human iPS culture medium containing bFGF except that it did not contain bFGF. In addition, a human iPS gel culture medium without bFGF was prepared, which was the same as the human iPS gel culture medium containing bFGF except that it did not contain bFGF. In addition, deacylated gellan gum (Nissan Chemical Industries, Ltd.) was added to a commercially available serum-free, allogeneic-free, and feeder-free culture medium for reprogramming at a concentration of 0.02% by weight to prepare a gel culture medium for comparison.
[0291] Here, the human iPS gel culture medium containing bFGF contained only bFGF at a concentration of about 1 / 25 of the bFGF concentration in the gel culture medium used for comparison.
[0292] During the culture on feeder cells, 300 μL / well of CTK solution was added to the 6-well culture dish containing iPS cells, and the 6-well culture dish was incubated in CO. 2 Incubate for 3 minutes in the incubator. After three minutes, the culture dish is taken out from the incubator. After confirming that only the feeder cells are detached from the culture dish, the CTK solution is removed with an aspirator. After removing the CTK solution, the iPS cells are washed once with PBS. 1mL of human iPS culture medium without bFGF is added thereto, and the iPS cells are scraped with a scraper and suspended in a 15mL centrifuge tube for about 10 times so as not to become a single cell. Then, 2mL of human iPS culture medium without bFGF is added thereto, and the mixture is divided into 3 equal portions, each 1mL, and these 3 equal portions are centrifuged at 270g using a centrifuge.
[0293] After centrifugation, the supernatant was removed from the 15 mL centrifuge tube, and 2 mL of the gel culture medium for comparison, the human iPS gel culture medium containing bFGF, or the human iPS gel culture medium without bFGF was added to the 15 mL centrifuge tube. From the second day on, 500 μL of the same gel culture medium as the initial gel culture medium was added to the centrifuge tube every day, and the iPS cells were floated and cultured for seven days.
[0294] Fig.11 (a) shows a typical example of colonies of iPS cells cultured in a floating manner for 7 days in a gel medium prepared from a commercially available feeder-free medium for comparison. Fig.11 (b) shows a typical example of colonies of iPS cells cultured in a human iPS gel medium containing bFGF for seven days in a floating manner. Fig.11 (c) shows a typical example of colonies of iPS cells cultured in a floating manner for 7 days in a human iPS gel medium without bFGF.
[0295] iPS cells could be cultured even in a human iPS gel medium not containing bFGF and a human iPS gel medium containing only bFGF at a concentration of about 1 / 25 of the bFGF concentration in the gel medium for comparison.
[0296] In order to confirm whether the colonies of iPS cells cultured for 7 days in floating culture were undifferentiated, iPS cells were seeded again on feeder cells, and the morphology of the colonies was observed. Fig.12 The upper photographs each show a colony in gel culture medium. Fig.12 The middle photographs of each show colonies two days after reseeding iPS cells that had been floating cultured for 7 days on feeder cells. In each case, it was confirmed that undifferentiated colonies accounted for 90% or more. These results indicate that iPS cells can be floated while maintaining their differentiated state even when using a gel medium that does not contain bFGF or a gel medium having a bFGF concentration 25 times or more lower than that of the gel medium used for comparison.
[0297] Fig.12 The lower photograph shows colonies seven days after reseeding iPS cells cultured for seven days in floating culture on feeder cells. These results indicate that iPS cells did not differentiate even after floating culture in gel medium followed by long-term (7-day) culture on feeder cells.
[0298] (Example 4)
[0299] The same human iPS medium without bFGF, human iPS gel medium containing bFGF, and human iPS gel medium without bFGF as in Example 3 were prepared. In addition, deacylated gellan gum (Nissan Chemical Industries, Ltd.) was added to a commercially available serum-free and feeder-free medium at a concentration of 0.02% by weight to prepare a gel medium for comparison. ROCK inhibitor was added to all gel mediums at a concentration of 10 μmol / L.
[0300] During the culture on feeder cells, 300 μL / well of CTK solution was added to the 6-well culture dish containing iPS cells, and the 6-well culture dish was incubated in CO. 2 Incubate in the incubator for 3 minutes. After three minutes, remove the culture dish from the incubator. After confirming that only the feeder cells have detached from the culture dish, remove the CTK solution with an aspirator. After removing the CTK solution, wash the iPS cells by adding PBS to the 6-well culture dish at 500 μL / well, and then remove the PBS from the 6-well culture dish. Add Accumax at 0.3 mL / well to the 6-well culture dish, and then place it in a CO 2The cells were incubated in an incubator for 5 minutes. Then, 0.7 mL / well of iPS medium containing bFGF was added to the 6-well culture dish to suspend the iPS cells until they became single cells.
[0301] After iPS cell suspension, 4 mL of human iPS culture medium without bFGF was added to a 15 mL centrifuge tube, and the iPS cell suspension was centrifuged at 270 g using a centrifuge. After centrifugation, the supernatant was removed and 1 mL of human iPS culture medium without bFGF was added to the centrifuge tube. The number of cells was counted using a hemocytometer.
[0302] Then, 5 × 10 5 2 mL of human iPS gel culture medium containing bFGF, human iPS gel culture medium without bFGF, or gel culture medium for comparison was added to the centrifuge tube. From the second day onwards, 500 μL of the same gel culture medium as the initial gel culture medium was added to the centrifuge tube every day, and the iPS cells were floated and cultured for seven days.
[0303] Therefore, if Fig.13 As shown in (c), iPS cells derived from a single cell cannot be cultured in the gel medium used for comparison. Fig.13 (a) and Fig.13 As shown in (b), iPS cells derived from a single cell can be cultured in a human iPS gel medium containing bFGF and a human iPS gel medium without bFGF. The human iPS gel medium containing bFGF has a bFGF concentration of 4 μg / mL, and the gel medium for comparison has a bFGF concentration of 100 μg / mL.
[0304] like Fig.14 As shown in the results of determining the number of colonies, the number of colonies formed by iPS cells floating cultured in a human iPS gel medium without bFGF was twice or more the number of colonies formed by iPS cells floating cultured in a human iPS gel medium containing bFGF. These results indicate that a low bFGF concentration or the absence of bFGF is preferred for the gel medium.
[0305] In addition, iPS cells were dissociated into single cells and cultured for 7 days using a medium to which a ROCK inhibitor was added at 10 μmol / L to a human iPS medium containing bFGF or a human iPS medium not containing bFGF supplemented with 0.02 wt % deacylated gellan gum. 5 Each cell was suspended in 1.5 mL of each gel medium, and ROCK inhibitor was added to 1.5 mL of each gel medium at 10 μmol / L every day.
[0306] A 10-fold amount of PBS was added to the iPS cells cultured for 7 days. After centrifugation at 270 g using a centrifuge, the supernatant was discarded, and 0.3 mL of Accumax was added to the culture container, which was then placed in a CO 2 chamber. 2 Incubate in an incubator for 5 minutes. Then, add 0.7 mL of human iPS culture medium containing bFGF to it so that the iPS cells are suspended until they become single cells. After suspension, add 1.5 mL of human iPS culture medium (a medium containing bFGF for cells cultured in a medium containing bFGF, or a medium without bFGF for cells cultured in a medium without bFGF), and the iPS cells are cultured for another 7 days using a centrifuge in the same manner as the previous 7 days. After cultivation, aliquots are re-seeded on feeder cells. After another three days, the cells are stained and observed with antibodies against NANOG and OCT3 / 4. The results are as follows Fig.15 iPS cells cultured in gel medium for a total of 14 days were positive for the undifferentiated markers NANOG and OCT3 / 4. These results indicate that iPS cells can be cultured in gel medium for a long time while maintaining their undifferentiated state, even when using gel medium without bFGF.
[0307] (Example 5)
[0308] The same human iPS medium without bFGF and human iPS gel medium without bFGF were prepared as in Example 3. A ROCK inhibitor was added to both gel mediums at a concentration of 10 μmol / L.
[0309] During the culture on feeder cells, 300 μL / well of CTK solution was added to the 6-well culture dish containing iPS cells, and the 6-well culture dish was incubated in CO. 2 Incubate in an incubator for 3 minutes. After three minutes, remove the culture dish from the incubator. After confirming that only the feeder cells have detached from the culture dish, remove the CTK solution with an aspirator. After removing the CTK solution, wash the iPS cells by adding PBS to the 6-well culture dish at 500 μL / well, and then remove the PBS. Add 0.3 mL / well of Accutase to the 6-well culture dish, and then place it in a CO 2 The cells were incubated in an incubator for 5 minutes. Then, 0.7 mL / well of human iPS medium without bFGF was added to the 6-well culture dish to suspend the iPS cells until they became single cells.
[0310] After iPS cell suspension, 4 mL of human iPS culture medium without bFGF was added to a centrifuge tube, and the iPS cell suspension was centrifuged at 270 g using a centrifuge. After centrifugation, the supernatant was removed and 1 mL of human iPS culture medium without bFGF was added to the centrifuge tube. The number of cells was counted using a hemocytometer.
[0311] Then, 1×10 5 , 2.5×10 5 or 5×10 5 iPS cells were cultured and 2 mL of human iPS gel medium without bFGF was added thereto. From the next day, 500 μL of gel medium was added to the centrifuge tube every day, and the iPS cells were floated and cultured for seven days.
[0312] Fig.16 The photographs of colonies at each inoculated cell number are shown. Fig.17 The results of determining the ratio of the number of iPS cells that formed colonies to the number of iPS cells seeded are shown. 5 The number of iPS cells seeded was 1×10 5 or 2.5 × 10 5 These results indicate that iPS cells seeded at low concentrations do not form colonies.
[0313] Place 1×10 5 iPS cells were added to the centrifuge tubes, and 200 μL, 400 μL, 1000 μL, or 2000 μL of human iPS gel medium without bFGF was added to the centrifuge tubes. From the next day, 100 μL, 200 μL, 5000 μL, or 1000 μL of gel medium was added to the centrifuge tubes every day, and the iPS cells were floated and cultured for 7 days.
[0314] Fig.18 The results of determining the ratio of the number of iPS cells that formed colonies to the number of iPS cells seeded are shown. These results indicate that as the amount of gel medium increases, in other words, as the seeding concentration of iPS cells decreases, iPS cells are less likely to form colonies.
[0315] (Example 6)
[0316] The same human iPS culture medium without bFGF and human iPS gel culture medium without bFGF as in Example 3 were prepared.
[0317] During the culture on feeder cells, 300 μL / well of CTK solution was added to the 6-well culture dish containing iPS cells, and the 6-well culture dish was incubated in CO. 2Incubate in an incubator for 3 minutes. After three minutes, remove the culture dish from the incubator. After confirming that only the feeder cells have detached from the culture dish, remove the CTK solution with an aspirator. After removing the CTK solution, wash the cells by adding PBS to the 6-well culture dish at 500 μL / well, and then remove the PBS. Add Accumax at 0.3 mL / well to the 6-well culture dish, and then place it in a CO 2 The cells were incubated in an incubator for 5 minutes. Then, 0.7 mL / well of human iPS medium without bFGF was added to the 6-well culture dish to suspend the iPS cells until they became single cells.
[0318] After iPS cell suspension, 4 mL of human iPS culture medium without bFGF was added to a 15 mL centrifuge tube, and the iPS cell suspension was centrifuged at 270 g using a centrifuge. After centrifugation, the supernatant was removed and 1 mL of human iPS culture medium without bFGF was added to a 15 mL centrifuge tube. The number of cells was counted using a hemocytometer.
[0319] Then, 2 mL of 5 × 10 5 The human iPS gel culture medium without bFGF for each iPS cell was placed in a dialysis module (Spectrum Laboratories G235035) equipped with a dialysis tube with a molecular weight cutoff of 100 kDa. No ROCK inhibitor was placed in the dialysis tube. Figure 5 As shown, the dialysis module is further placed in a 50mL centrifuge tube, and 20mL of human iPS gel culture medium without bFGF is placed around the dialysis tube in the centrifuge tube. ROCK inhibitor is further added to the human iPS gel culture medium without bFGF around the dialysis tube at a final concentration of 10μmol / L. As a control, ROCK inhibitor was not added to some centrifuge tubes. Then, 10mL of human iPS gel culture medium without bFGF around the dialysis tube was replaced with fresh gel culture medium every two days, and floating culture was continued for 7 days. The fresh human iPS gel culture medium without bFGF to be placed for replacement contains a ROCK inhibitor at a concentration of 10μmol / L.
[0320] like Fig. 20 As shown, Fig.19 Compared with the culture in which the human iPS gel culture medium without bFGF and ROCK inhibitor was placed around the dialysis tube as shown in (a), the Fig.19 (b) In the culture in which a human iPS gel culture medium without bFGF supplemented with a ROCK inhibitor was placed around the dialysis tube, iPS cells significantly formed colonies.
[0321] These results indicate that low molecules such as ROCK inhibitors pass through the membrane of the dialysis tube. These results also indicate that iPS cells can be cultured while maintaining the concentrations of the medium components in the dialysis tube.
[0322] (Example 7)
[0323] The same human iPS culture medium without bFGF and human iPS gel culture medium without bFGF as in Example 3 were prepared.
[0324] During the culture on feeder cells, 300 μL / well of CTK solution was added to the 6-well culture dish containing iPS cells, and the 6-well culture dish was incubated in CO. 2 Incubate in the incubator for 3 minutes. After three minutes, remove the culture dish from the incubator. After confirming that only the feeder cells have detached from the culture dish, remove the CTK solution with an aspirator. After removing the CTK solution, wash the cells by adding PBS to the 6-well culture dish at 500 μL / well, and then remove the PBS from the 6-well culture dish. Add Accumax at 0.3 mL / well to the 6-well culture dish, and then place it in a CO 2 The cells were incubated in an incubator for 5 minutes. Then, 0.7 mL / well of human iPS medium without bFGF was added to the 6-well culture dish to suspend the iPS cells until they became single cells.
[0325] After iPS cell suspension, 4 mL of human iPS culture medium without bFGF was added to a 15 mL centrifuge tube, and the iPS cell suspension was centrifuged at 270 g using a centrifuge. After centrifugation, the supernatant was removed and 1 mL of human iPS culture medium without bFGF was added to the centrifuge tube. The number of cells was counted using a hemocytometer.
[0326] Then, 2 mL of 5 × 10 5 The human iPS gel culture medium without bFGF of each iPS cell is placed in the dialysis tubing of the dialysis module. Further the dialysis module is placed in a 50mL centrifuge tube (Corning352070), and 20mL of the human iPS gel culture medium without bFGF is placed in the centrifuge tube around the dialysis tube. Further ROCK inhibitor is added to the human iPS gel culture medium without bFGF around the dialysis tube with 10 μmol / L. Then, the human iPS gel culture medium without bFGF around the dialysis tube of 10mL is replaced with fresh gel culture medium every two days, and floating culture is continued for 7 days. The fresh human iPS gel culture medium without bFGF to be placed for replacement contains a ROCK inhibitor with a concentration of 10 μmol / L. As a control, floating culture is continued for seven days in some centrifuge tubes without replacing the human iPS gel culture medium without bFGF around the dialysis tube.
[0327] like Fig. 22 As shown, Fig.21 (b) Compared with the case where the human iPS gel medium without bFGF around the dialysis tube was not replaced, Fig.21 When the human iPS gel medium without bFGF around the dialysis tube was replaced with fresh gel medium as shown in (a), the single colonies formed by iPS cells were found to be larger. These results indicate that replacing the human iPS gel medium without bFGF around the dialysis tube promoted the proliferation of iPS cells.
[0328] The iPS cell colonies cultured for 7 days were further re-seeded on feeder cells, and the undifferentiated state of the iPS cells was confirmed to be maintained based on the morphology of the colonies. Fig.23 and Fig.24 As shown, even if the bFGF-free human iPS gel culture medium surrounding the dialysis tube was replaced or not, 80% or more of the colonies maintained their undifferentiated state.
[0329] (Example 8)
[0330] The same human iPS culture medium without bFGF and human iPS gel culture medium without bFGF as in Example 3 were prepared.
[0331] During the culture on feeder cells, 300 μL / well of CTK solution was added to the 6-well culture dish containing iPS cells, and the dish was incubated under CO. 2 Incubate in the incubator for 3 minutes. After three minutes, remove the culture dish from the incubator. After confirming that only the feeder cells have detached from the culture dish, remove the CTK solution with an aspirator. After removing the CTK solution, wash the cells by adding PBS to the 6-well culture dish at 500 μL / well, and then remove the PBS. Add Accumax at 0.3 mL / well to the 6-well culture dish, and then place it in a CO 2 The cells were incubated in an incubator for 5 minutes. Then, 0.7 mL / well of human iPS medium without bFGF was added to the 6-well culture dish to suspend the iPS cells until they became single cells.
[0332] After iPS cell suspension, 4 mL of human iPS culture medium without bFGF was added to a 15 mL centrifuge tube, and the iPS cell suspension was centrifuged at 270 g using a centrifuge. After centrifugation, the supernatant was removed and 1 mL of human iPS culture medium without bFGF was added to the centrifuge tube. The number of cells was counted using a hemocytometer.
[0333] Then, 2 mL of 5 × 10 5The human iPS gel culture medium without bFGF of each iPS cell is placed in the dialysis tube of the dialysis module. The dialysis module is further placed in a 50mL centrifuge tube, and 20mL of the human iPS gel culture medium without bFGF is placed around the dialysis tube in the centrifuge tube. ROCK inhibitor is further added to the human iPS gel culture medium without bFGF around the dialysis tube at 10μmol / L. Then, the human iPS gel culture medium without bFGF around the dialysis tube of 10mL is replaced with fresh gel culture medium every two days, and floating culture is continued for 7 days. The fresh human iPS gel culture medium without bFGF to be placed for replacement contains a ROCK inhibitor at a concentration of 10μmol / L.
[0334] As the first control, 2 mL of 5 × 10 5 The human iPS gel culture medium without bFGF of each iPS cell was placed in the dialysis tube of the dialysis module. The dialysis tube was further placed in a 50mL centrifuge tube, and 20mL of human iPS culture medium without bFGF and gellan gum was placed around the dialysis tube in the centrifuge tube. ROCK inhibitor was further added to the human iPS culture medium without bFGF and gellan gum around the dialysis tube at 10μmol / L. Then, 10mL of human iPS culture medium without bFGF and gellan gum around the dialysis tube was replaced with fresh culture medium every two days, and floating culture was continued for 7 days.
[0335] As a second control, 2 mL of 5 × 10 5 The human iPS gel medium without bFGF containing 10 iPS cells was placed in a 50 mL centrifuge tube without using a dialysis tube. Then, 500 μL of the human iPS gel medium without bFGF was added to the 50 mL centrifuge tube once a day, and the floating culture was continued for seven days.
[0336] Therefore, if Fig.25 and Fig.26 As shown, the use of the dialysis tube increased the number of iPS cell colonies compared to not using the dialysis tube. In addition, the use of the human iPS gel medium without bFGF around the dialysis tube increased the number of iPS cell colonies compared to the use of the human iPS medium without bFGF and gellan gum around the dialysis tube.
[0337] (Example 9: Induction of iPS cells in polymer culture medium)
[0338] 500 mL of Primate ES cell culture medium (ReproCELL Co., Ltd.) and 0.2 mL of bFGF (Gibco PHG0266) at a concentration of 10 μg / mL were mixed to prepare a human iPS culture medium containing bFGF. In addition, a human iPS culture medium without bFGF was prepared from 500 mL of Primate ES cell culture medium (ReproCELL Co., Ltd.) without mixing with bFGF (Gibco PHG0266). In addition, a commercially available serum-free and feeder-free culture medium was prepared.
[0339] Deacetylated gellan gum (Nissan Chemical Industries, Ltd.) was added at a concentration of 0.02% by weight to a human iPS medium not containing bFGF, a human iPS medium containing bFGF, and a commercially available serum-free medium and feeder-free medium to prepare a human iPS gel medium not containing bFGF, a human iPS gel medium containing bFGF, and a gel medium for comparison.
[0340] OCT3 / 4, SOX2, KLF4, and c-MYC were transferred into human fibroblasts using retrovirus. After 7 days of floating culture, 1×10 5 The cells were suspended in a human iPS gel medium without bFGF, and cultured in a human iPS gel medium without bFGF, a human iPS gel medium containing bFGF, or a gel medium for comparison. Thus, iPS cells were produced. Fig. 27 Therefore, iPS cells produced in human iPS gel medium without bFGF were re-seeded on feeder cells. Two days later, colonies were confirmed morphologically, so Fig.28 As shown in (a), this colony is an undifferentiated iPS cell colony. Fig.28 (b) and Fig.28 As shown in (c), iPS cells were further stained with antibodies against OCT3 / 4 and NANOG, and the iPS cells were positive for these antibodies. These results indicate that iPS cells can be induced in polymer culture medium.
[0341] (Example 10: Clonality of iPS cells induced in polymer culture medium)
[0342] During the culture process, 300 μL of CTK solution was added to a 6 cm dish containing iPS cells induced in the polymer medium, and the dish was placed under CO. 2Incubate in an incubator for 3 minutes. After three minutes, remove the culture dish from the incubator. After confirming that only the feeder cells have detached from the culture dish, remove the CTK solution with an aspirator. After removing the CTK solution, wash the iPS cells by adding 500 μL of PBS to the culture dish, and then remove the PBS. Add 0.3 mL of dissociation solution (Accumax) to the culture dish, and then place it in a CO 2 The cells were incubated in an incubator for 5 minutes. Then, 0.7 mL of iPS medium without bFGF was added to the culture dish to suspend the iPS cells until they became single cells.
[0343] After iPS cell suspension, 4 mL of iPS culture medium without bFGF was added to the centrifuge tube, and the iPS cell suspension was centrifuged at 270 g using a centrifuge. After centrifugation, the supernatant was removed and 1 mL of iPS culture medium without bFGF was added thereto. The number of cells was counted using a hemocytometer. After cell counting, 2.5 × 10 5 After staining, the stained cells were mixed and 5×10 5 iPS cells were inoculated into non-adhesive culture dishes or 15 mL tubes and then floated without stirring. In a 15 mL tube, 2 mL of human iPS gel culture medium without bFGF was used. In a non-adhesive culture dish, 2 mL of human iPS culture medium without bFGF and gellan gum was used. ROCK inhibitor (Selleck Chemicals S1049) was added to each culture medium at a concentration of 10 μmol / L. Then, 500 μL of human iPS culture medium without bFGF was added to 15 mL tubes and non-adhesive culture dishes every day. Fresh human iPS gel culture medium without bFGF to be placed for replacement contains ROCK inhibitor at a concentration of 10 μmol / L. ROCK inhibitor was added to 15 mL tubes and non-adhesive culture dishes at a final concentration of 10 μmol / L every day, and floating culture was continued for seven days.
[0344] Therefore, if Fig.29 As shown in (a), when iPS cells were cultured in a non-adhesive culture dish using a medium without gellan gum, aggregation between iPS cell colonies with different staining was significantly observed. As a result of quantification, 40% or more of the cells were aggregated. In contrast, Fig.29 As shown in (b), when iPS cells were cultured in a 15 mL tube using human iPS gel medium without bFGF, such aggregation was not observed.
[0345] (Example 11)
[0346] After iPS cells were suspended, 4 mL of human iPS culture medium containing bFGF was added to a 15 mL centrifuge tube, and the iPS cell suspension was centrifuged at 270 g using a centrifuge. After centrifugation, the supernatant was removed, and 1 mL of human iPS culture medium containing bFGF was added to the 15 mL centrifuge tube. The number of cells was counted using a hemocytometer. After cell counting, 5 × 10 5 iPS cells were seeded into a 15 mL Falcon tube (R) (Corning 352096) or a non-adherent culture dish, and then cultured in a floating state without stirring.
[0347] The culture medium used is 2mL of human iPS gel culture medium containing bFGF or human iPS culture medium containing bFGF and not containing gellan gum, and iPS cells are cultured in tubes or non-adhesive culture dishes for 5 to 7 days. ROCK inhibitor (Selleck Chemicals S1049) is added to each culture medium at 10 μmol / L. Then, 500 μL of human iPS culture medium containing bFGF and gellan gum or human iPS culture medium containing bFGF and not containing gellan gum is added to 15mL of tubes and non-adhesive culture dishes every day. ROCK inhibitor is added to 15mL of tubes and non-adhesive culture dishes at a final concentration of 10 μmol / L every day, and floating culture is continued for 5 to 7 days.
[0348] Fig.30 (a) is a photograph showing iPS cells cultured in a human iPS medium containing bFGF and no gellan gum in a tube. In this case, the iPS cells precipitated and could not be cultured. Fig.30 (b) is a photograph showing iPS cells cultured in a human iPS medium containing bFGF and gellan gum in a tube. In this case, the iPS cells neither precipitated nor aggregated. Fig.30 (c) is a photograph showing iPS cells cultured in a culture dish in a human iPS medium containing bFGF and no gellan gum. In this case, iPS cells aggregated and could not be cultured. Fig.30 (d) is a photograph showing iPS cells cultured in a culture dish in a human iPS medium containing bFGF and gellan gum. In this case, iPS cells aggregated and could not be cultured.
[0349] (Example 12)
[0350] The same human iPS culture medium without bFGF and human iPS gel culture medium without bFGF were prepared as in Example 3. In addition, a commercially available serum-free and feeder-free culture medium was prepared.
[0351] A grid plate (Spheroid Generator MPs 500 and MPc 500, Kuraray Co., Ltd.) provided with a plurality of through holes having an upper opening diameter of 0.8 mm and a lower opening diameter of 0.5 mm forming a grid pattern was prepared.
[0352] During the culture on feeder cells, 300 μL / well of CTK solution was added to the 6-well culture dish containing iPS cells, and the 6-well culture dish was incubated in CO. 2 Incubate in the incubator for 3 minutes. After three minutes, remove the culture dish from the incubator. After confirming that only the feeder cells have detached from the culture dish, remove the CTK solution with an aspirator. After removing the CTK solution, wash the cells by adding PBS to the culture dish at 500 μL / well, and then remove the PBS. Add Accumax at 0.3 mL / well to the culture dish, and then place it in a CO 2 The cells were incubated in an incubator for 5 minutes. Then, 0.7 mL / well of human iPS medium without bFGF was added to the culture dish to suspend the iPS cells until they became single cells.
[0353] Then, 4 mL of human iPS culture medium without bFGF was added to a 15 mL centrifuge tube, and the iPS cell suspension was centrifuged at 270 g using a centrifuge. After centrifugation, the supernatant was removed and 1 mL of human iPS culture medium without bFGF was added to the centrifuge tube. The number of cells was counted using a hemocytometer.
[0354] Then, 2.5×10 5 iPS cells were seeded on each grid plate and cultured using each through-hole of the grid plate for two days to form Fig.31 (a) shows colonies of uniform size. Next, the uniformly sized colonies are placed in 2 mL of human iPS gel culture medium without bFGF, and the human iPS gel culture medium without bFGF containing the colonies is placed in the dialysis tube of the dialysis module. The dialysis module is further placed in a 50 mL centrifuge tube, and 20 mL of commercially available serum-free and feeder-free culture medium without gellan gum is placed around the dialysis tube in the centrifuge tube. Then, the commercially available serum-free and feeder-free culture medium without gellan gum around 10 mL of the dialysis tube is replaced with fresh culture medium every two days, and floating culture is continued for 7 days. The fresh culture medium to be placed for replacement contains a ROCK inhibitor at a concentration of 10 μmol / L.
[0355] After 7 days of floating culture, Fig.31 (b) and Fig.32 As shown, an increase in the size of iPS cell colonies was observed. These results indicate that iPS cell colonies proliferated.
[0356] The floating iPS cell colonies were then re-seeded on feeder cells. Three days later, the morphology of the colonies confirmed that the undifferentiated state of the iPS cells was maintained. Fig.33 and Fig.34 As shown, all colonies were undifferentiated. These results suggest that the size of iPS cell colonies can be made uniform in grid plates and that iPS cells can then be cultured in polymer medium while maintaining their undifferentiated state.
[0357] (Fifth Embodiment)
[0358] The method for producing induced pluripotent stem (iPS) cells according to an embodiment of the present invention comprises: preparing somatic cells; and transferring RNA encoding a reprogramming factor into the somatic cells by lipid transfection.
[0359] The somatic cells are, for example, blood cells. The blood cells are separated from the blood. The blood is, for example, peripheral blood or umbilical cord blood, but the blood is not limited thereto. The blood may be collected from an adult or from a minor. For blood collection, an anticoagulant such as ethylenediaminetetraacetic acid (EDTA), heparin, or citrate dextrose formula A solution (ACD-A solution) is used.
[0360] Blood cells are, for example, nucleated cells such as monocytes, neutrophils, basophils or lymphocytes, and do not include erythrocytes, granulocytes and platelets. Blood cells may be, for example, endothelial progenitor cells, hematopoietic stem / progenitor cells, T cells or B cells. T cells are, for example, αβ T cells.
[0361] The mononuclear cells are separated from the blood using a blood cell separation medium and a centrifugal separation device, etc. When Ficoll (GE Healthcare Japan Co., Ltd.) is used as a blood cell separation medium, the method of separating the mononuclear cells is as follows.
[0362] The accuracy of monocyte separation tends to deteriorate at low temperatures. Therefore, the centrifuge is set to 4 ° C to 42 ° C, preferably 18 ° C. Collect 10 μ L to 50 mL of blood from an adult or a minor, and add a chelating agent containing EDTA to the blood so that the blood does not coagulate, and then gently mix. Human lymphocyte separation medium (Ficoll-Paque PREMIUM, GE Healthcare Japan Co., Ltd.) is distributed in two 15 mL tubes with 5 mL / tube. 5 mL of PBS is added to 5 mL of blood for dilution, and 5 mL of the diluted blood is layered on the human lymphocyte separation medium in each tube. At this time, the diluted blood is slowly added to the medium so that the blood flows downward along the tube wall, thereby not interfering with the interface.
[0363] The solution in each tube is centrifuged at 10×g to 1000×g, preferably 400×g for 5 minutes to 2 hours, preferably 30 minutes at 4°C to 42°C, preferably 18°C. After centrifugation, a white turbid middle layer appears in the tube. The white turbid middle layer contains mononuclear cells. The white turbid middle layer in the tube is gradually recovered with a Pipetman and transferred to a new 15mL tube. In this operation, it is necessary to avoid sucking out the lower layer. The white turbid middle layer of about 1mL can be recovered from one tube. The middle layers from two tubes are transferred to one tube together.
[0364] 1 mL to 48 mL, preferably 12 mL of PBS is added to the recovered mononuclear cells, and the solution is further centrifuged at 4°C to 42°C, preferably 18°C, at 10 × g to 1000 × g, preferably 200 × g for 1 minute to 60 minutes, preferably ten minutes. Then, the supernatant of the solution is sucked off using an aspirator, and the mononuclear cells are suspended by adding 1 mL to 12 mL, preferably 3 mL of a serum-free hematopoietic cell culture medium (X-VIVO (R) 10, Lonza Japan Co., Ltd.) having a known composition to obtain a mononuclear cell suspension. A 10 μL aliquot of the mononuclear cell suspension is stained with Trypan Blue and counted using a hemocytometer.
[0365] In the case where Vacutainer(R) (Becton, Dickinson and Company) is used as a blood collection tube, the method for separating mononuclear cells is as follows.
[0366] The accuracy of monocyte separation tends to deteriorate at low temperatures. Therefore, the centrifuge is set to 4°C to 42°C, preferably 18°C. 8mL of blood is collected from an adult or a minor using a blood collection tube (Vacutainer (R), Becton, Dickinson and Company) and mixed with an anticoagulant by inversion. Then, the balance is adjusted and the solution is centrifuged at 4°C to 42°C, preferably 18°C, at 100×g to 3000×g, preferably 1500×g to 1800×g for 1 minute to 60 minutes, preferably 20 minutes. After centrifugation, the upper layer, i.e. the plasma layer, is removed, and the mononuclear cell layer and the blood cells adhered to the gel are suspended by pipetting to obtain a suspension. The obtained suspension is transferred to another 15mL tube.
[0367] 1 mL to 14 mL, preferably 12 mL of PBS is added to the suspension in a 15 mL tube, and the suspension is centrifuged at 100 × g to 3000 × g, preferably 200 × g, for 1 minute to 60 minutes, preferably 5 minutes at 4 ° C to 42 ° C, preferably at 18 ° C. After centrifugation, the supernatant is removed using an aspirator. The hematopoietic agent (PharmLyse (R), x10 concentrate, Becton, Dickinson and Company) is diluted to x1 concentration with sterile water. The pellet in the 15 mL tube is dissociated by tapping, and 1 mL to 14 mL, preferably 1 mL of the hematopoietic agent is added thereto. Then, the solution is allowed to stand in the dark at room temperature for 1 minute to 60 minutes, preferably 1 minute.
[0368] Next, 1 mL to 14 mL, preferably 12 mL of PBS is added to a 15 mL tube, and the solution is centrifuged at 4 ° C to 42 ° C, preferably at room temperature, at 100 × g to 3000 × g, preferably 200 × g, for 1 minute to 60 minutes, preferably 5 minutes. After centrifugation, the supernatant is removed with an aspirator, and 1 mL to 15 mL, preferably 3 mL of a serum-free hematopoietic cell culture medium (X-VIVO (R) 10, Lonza Japan Co., Ltd.) with a known composition is added to suspend the mononuclear cells to obtain a mononuclear cell suspension. A 10 μL aliquot of the mononuclear cell suspension is stained with Trypan Blue and counted using a hemocytometer.
[0369] The method for separating monocytes from blood is not limited to the above method, for example, dialysis membrane can be used to separate monocytes from blood. In addition, PurecellSelect system (R) (Pall Co., Ltd.) for whole blood MNC enrichment, purifier for removing blood cells (Cellsorba E (R), Asahi Kasei Co., Ltd.) and leukocyte removal filter (Sepacell PL (R), PLX-5B-SCD, Asahi Kasei Co., Ltd.) for platelet concentrate can be used.
[0370] CTL-UP1 purchased from Cellular Technology Limited, PBMC-001 purchased from Sanguine Biosciences Co., Ltd., and the like can be used as mononuclear cells.
[0371] Alternatively, blood cells cryopreserved using a cell cryopreservation solution such as Cellbanker 1, GMP grade Stem-Cellbanker, or DMSO-free GMP grade Stem-Cellbanker (Nippon Zenyaku Kogyo Co., Ltd.) may be thawed and used as blood cells.
[0372] To thaw the monocytes, first 1 mL to 15 mL, preferably 8 mL of a serum-free hematopoietic cell culture medium (X-VIVO (R) 10, Lonza Japan Co., Ltd.) with a known composition is placed in a 15 mL tube in advance, and the tube containing the frozen monocytes is placed in a warm bath at 4°C to 42°C, preferably 37°C to start thawing the monocytes. Then, the tube containing the monocytes, which still has a small amount of ice, is taken out of the warm bath, and the monocytes are transferred to a tube containing a serum-free hematopoietic cell culture medium with a known composition. A 10 μL aliquot of the monocyte suspension is stained with Trypan Blue and counted using a hemocytometer.
[0373] Blood cells can be separated according to their cell surface markers. Hematopoietic stem / progenitor cells are positive for CD34. T cells are positive for any one of CD3, CD4 and CD8. B cells are positive for any one of CD10, CD19 and CD20. Hematopoietic stem / progenitor cells, T cells or B cells are separated from blood cells using, for example, an automatic magnetic cell separation device. Alternatively, pre-separated monocytes can be prepared. However, reprogramming factor RNA can be transferred to blood cells that have not yet been separated according to cell surface markers.
[0374] CD34-positive cells are stem / progenitor cells and are prone to reprogramming. When iPS cells are produced using T cells that are CD3-positive cells, iPS cells derived from T cells retain the TCR recombination system and are therefore easily induced to differentiate into T cells with high efficiency.
[0375] The method for isolating CD34 positive cells is as follows.
[0376] Add 10 μL of IL-6 (100 μg / mL), 10 μL of SCF (300 μg / mL), 10 μL of TPO (300 μg / mL), 10 μL of Flt3 ligand (300 μg / mL) and 10 μL of IL-3 (10 μg / mL) to 10 mL of serum-free culture medium (StemSpan H3000, STEMCELL Technologies, Inc.) to prepare a blood cell culture medium (hematopoietic stem / progenitor cell culture medium).
[0377] 1 mL to 6 mL, preferably 2 mL of blood cell culture medium is placed in one well of a 6-well plate. In order to prevent evaporation of the culture medium, 1 mL to 6 mL, preferably 2 mL of PBS is placed in each of the remaining five wells. Then, the 6-well plate is placed in an incubator at 4° C. to 42° C., preferably 37° C., and incubated.
[0378] Prepare a column buffer containing 10 μL to 1 mL, preferably 80 μL, of EDTA (500 mmol / L) and 10 μL to 1 mL, preferably 200 μL of FBS added to 20 mL of PBS. 4 Up to 1×10 9 , preferably 2×10 7 The mononuclear cell suspension of 100 monocytes is dispensed into a 15 mL tube, and the mononuclear cell suspension is centrifuged at 100 × g to 3000 × g, preferably 300 × g, for 10 minutes at 4° C. to 42° C., preferably 4° C. After centrifugation, the supernatant is removed and the mononuclear cells are suspended in 100 μL to 1 mL, preferably 300 μL, of column buffer.
[0379] 10 μL to 1 mL, preferably 100 μL of FcR blocking reagent (Miltenyi Biotec KK) and 10 μL to 1 mL, preferably 100 μL of CD34 microbead kit (Miltenyi Biotec KK) are added to the monocyte suspension in a 15 mL tube. The FcR blocking reagent is used to enhance the specificity of microbead labeling. The monocyte suspension is then mixed and allowed to stand at 4° C. to 42° C., preferably 4° C. for 1 minute to 2 hours, preferably 30 minutes.
[0380] Next, the mononuclear cell suspension in the 15 mL tube is diluted by adding 1 mL to 15 mL, preferably 10 mL, of column buffer and centrifuged at 100 × g to 1000 × g, preferably 300 × g, for 1 minute to 2 hours, preferably 10 minutes at 4° C. to 42° C., preferably 4° C. After centrifugation, the supernatant in the 15 mL tube is removed using an aspirator, and the mononuclear cells are resuspended by adding 10 μL to 10 mL, preferably 500 μL of column buffer.
[0381] The automatic magnetic cell separation device column (MS column, Miltenyi Biotec KK) is attached to the automatic magnetic cell separation device (MiniMACS separation unit, Miltenyi Biotec KK), and the column is washed by adding 10 μL to 10mL, preferably 500 μL of column buffer. Next, monocytes are placed in the column. Further 10 μL to 10mL, preferably 500 μL of column buffer is placed in the column, and the column is washed once to ten times, preferably three times. Then, the column is removed from the automatic magnetic cell separation device, and placed in the tube of 15mL. Then, 10 μL to 10mL, preferably 1000 μL of column buffer is placed in the column, and the syringe is immediately pushed to elute CD34 positive cells into the tube of 15mL.
[0382] 10 μL of the CD34-positive cell suspension is stained with Trypan Blue, and the number of cells is counted using a hemocytometer. The CD34-positive cell suspension in a 15 mL tube is centrifuged at 100×g to 1000×g, preferably 300×g, at 4°C to 42°C, preferably 4°C, for 1 minute to 2 hours, preferably ten minutes. After centrifugation, the supernatant is removed using an aspirator. In addition, the CD34-positive cells are resuspended in a pre-warmed blood cell culture medium, and the CD34-positive cells are seeded on a culture plate. Then, the CD34-positive cells are incubated at 4°C to 42°C, preferably 37°C, in a CO atmosphere of 1% to 20%, preferably 5%. 2 The culture medium was cultured for 6 days in the environment. During this culture period, medium replacement may not be necessary.
[0383] The method for isolating cells based on markers other than CD34 is the same as the method for isolating CD34-positive cells.
[0384] The blood cells to which the reprogramming factor RNA is to be transferred are cultured, for example, in a T cell culture medium or a hematopoietic stem / progenitor cell culture medium. In the case of producing iPS cells derived from T cells, a T cell culture medium is used. In the case of producing iPS cells from CD34-positive cells, a hematopoietic stem / progenitor cell culture medium is used. The culture conditions include, for example, 5% CO 2 concentration, an oxygen concentration of 25% or less, and a temperature of 37°C or less.
[0385] The blood cells to which the reprogramming factor RNA is to be transferred are cultured in a feeder-free manner using a basement membrane matrix such as Matrigel (Corning Inc.), CELLstart(R) (Thermo Fisher Scientific Inc.), or Laminin511 (Nippi Inc.).
[0386] The following culture media can be used: Primate ES cell medium, Reprostem, ReproFF, ReproFF2, ReproXF (ReproCELL Co., Ltd.), mTeSR1, TeSR2, TeSRE8, ReproTeSR (STEMCELL Technologies Co., Ltd.), PluriSTEM(R) human ES / iPS medium (Merck KGaA), NutriStem(R) XF / FF medium for human iPS and ES cells, Pluriton reprogramming medium (Stemgent Co., Ltd.), PluriSTEM(R), StemFitAK02N, StemFit AK03 (Ajinomoto Co., Ltd.), serum-free and feeder-free medium ESC-Sure(R) for hESC / iPS (Applied StemCell Co., Ltd.), and L7(R) hPSC culture system (Lonza Japan Co., Ltd.).
[0387] For floating culture, blood cells are placed in a rotating bottle and cultured under stirring. Alternatively, blood cells can be placed in a 0.001% to 10% gellan gum solution (selected from at least one polymer compound in the group consisting of deacetylated gellan gum, hyaluronic acid, rhamnose gum, diutan gum, xanthan gum, carrageenan, fucoidan, pectin, pectic acid, pectinic acid, heparan sulfate, heparan, heparin sulfate, keratan sulfate, chondroitin sulfate, dermatan sulfate, rhamnosyl sulfate and salts thereof), or a thermosensitive gel and cultured. The gel culture medium may contain methylcellulose. The methylcellulose contained therein inhibits aggregation between cells.
[0388] The thermosensitive gel may contain at least one selected from the following: poly(glycerol monomethacrylate) (PGMA), poly(2-hydroxypropyl methacrylate) (PHPMA), polyisopropylacrylamide, poly(N-isopropylacrylamide) (PNIPAM), amine-terminated, carboxylic acid-terminated, maleimide-terminated, N-hydroxysuccinimide (NHS) ester-terminated, triethoxysilane-terminated, poly(N-isopropylacrylamide-co-acrylamide), poly(N-isopropylacrylamide-co-acrylic acid), poly(N-isopropylacrylamide-co-butyl acrylate), poly(N-isopropylacrylamide-co-methacrylic acid), poly(N-isopropylacrylamide-co-methacrylic acid-co-octadecyl acrylate) and N-isopropylacrylamide.
[0389] The culture medium may contain at least one substance selected from the group consisting of cadherin, laminin, fibronectin, and vitronectin.
[0390] Reprogramming factor RNA is transferred to blood cells.Reprogramming factor RNA includes, for example, Oct3 / 4 mRNA, Sox2 mRNA, Klf4 mRNA and c-Myc mRNA.Reprogramming factor RNA may also include mRNA of at least one factor selected from the group consisting of the following: LIN28A, LIN28B, GLIS1, FOXH1, p53-dominant negative, p53-P275S, L-MYC, NANOG, DPPA2, DPPA4, DPPA5, ZIC3, BCL-2, E-RAS, TPT1, SALL2, NAC1, DAX1, TERT, ZNF206, FOXD3, REX1, UTF1, KLF2, KLF5, ESRRB, miR-291-3p, miR-294, miR-295, NR5A1, NR5A2, TBX3, MBD3sh, TH2A and TH2B. These mRNAs can be purchased from TriLink BioTechnologies, Inc.
[0391] Each mRNA may be modified with at least one selected from the group consisting of pseudouridine (Ψ), 5-methyluridine (5meU), N1-methylpseudouridine (me1Ψ), 5-methoxyuridine (5moU), 5-hydroxymethyluridine (5hmU), 5-formyluridine (5fU), 5-carboxymethyluridine (5camU), thienylguanosine (thG), N4-methylcytidine (me4C), 5-methylcytidine (m5C), 5-methoxycytidine (5moC), 5-hydroxymethylcytidine (5hmC), 5-hydroxycytidine (5hoC), 5-formylcytidine (5fC), 5-carboxycytidine (5caC), N6-methyl-2-aminoadenosine (m6DAP), diaminopurine (DAP), 5-methyluridine (m5U), 2'-O-methyluridine (Um or m2'-OU), 2-thiouridine (s2U) and N6-methyladenosine (m6A).
[0392] mRNA can be polyadenylated.
[0393] mRNA can be prepared by polyadenylation of in vitro transcribed (IVT) RNA. By using a DNA template encoding a poly(A) tail, the mRNA can be polyadenylated during IVT. The mRNA can be capped. In order to maximize the expression efficiency in the cell, it is preferred that the vast majority of mRNA molecules should contain a cap. The mRNA can have a 5' cap [m7G(5')PPP(5')G] structure. This sequence stabilizes the mRNA and promotes mRNA transcription. From mRNA with a 5' triphosphate, the 5' triphosphate can be removed by dephosphorylation. The mRNA can have [3'O-Me-m7G(5')ppp(5')G] as an anti-reverse transcription cap analog (ARCA). ARCA is a sequence inserted upstream of the transcription start point and doubles the mRNA transcription efficiency. The mRNA can have a poly(A) tail.
[0394] mRNA can be a replicating RNA with self-propagation ability. Replicating RNA is RNA with self-propagation ability, which, unlike ordinary RNA, also has the ability to express proteins necessary for RNA replication. Replicating RNA is derived from Venezuelan equine encephalitis (VEE) virus, which is an alpha virus. After lipid transfection of cells with replicating RNA, RNA that continuously produces reprogramming factors can be expressed in cells. Therefore, it is possible to eliminate the need to add RNA every day.
[0395] The sequence of the replicating RNA may include a sequence obtained from an alphavirus replicon RNA or an alphavirus selected from the group consisting of Eastern equine encephalitis (EEE) virus, Venezuelan equine encephalitis (VEE) virus, Evograine virus, Merkabo virus, Napishuna virus, and Western equine encephalitis virus (WEE).
[0396] The replicating RNA may also include a sequence obtained from an alphavirus selected from the group consisting of Sindbis virus, Semliki Forest virus, Middelburg virus, Chikungunya virus, Oneon virus, Ross River virus, Bama Forest virus, Geta virus, Lushan virus, Bibaru virus, Mayaro virus, Una virus, Ora virus, Wataroa virus, Babanken virus, Zilagachi virus, Highland J virus, Fort Morgan virus, Ndumou virus, and Boji River virus.
[0397] The replicating RNA contains (VEE RNA replicase)-(promoter)-(RF1)-(self-cleaving peptide)-(RF2)-(self-cleaving peptide)-(RF3)-(IRES or core promoter)-(RF4)-(IRES or any promoter)-(any selectable marker)-(VEE 3'UTR and poly(A) tail)-(any selectable marker)-promoter in the 5'→3' direction. RF1-4 are factors that induce somatic cells to dedifferentiate into pluripotent cells. RF2-3, RF3-4 and RF4 are arbitrarily selected. RF1 to RF4 can be selected from the group consisting of Oct-4, Klf4, Sox-2, c-Myc, LIN28A, LIN28B, GLIS1, FOXH1, p53-dominant negative, p53-P275S, L-MYC, NANOG, DPPA2, DPPA4, DPPA5, ZIC3, BCL-2, E-RAS, TPT1, SALL2, NAC1, DAX1, TERT, ZNF206, FOXD3, REX1, UTF1, KLF2, KLF5, ESRRB, miR-291-3p, miR-294, miR-295, NR5A1, NR5A2, TBX3, MBD3sh, TH2A and TH2B.
[0398] Reprogramming factor RNA is transferred into blood cells by, for example, lipofection. Lipofection is a method involving the formation of a complex of nucleic acid (negatively charged substance) and positively charged lipids through electrical interaction, and the entry of the complex into cells by endocytosis or membrane fusion. Lipofection has advantages such as little cell damage, excellent transfer efficiency, easy operation, and short duration.
[0399] For example, short interfering RNA (siRNA) or lipofection reagent is used in lipofection with reprogramming factor RNA. siRNA lipofection reagent and mRNA lipofection reagent can be used as RNA transfection reagent. More specifically, for example, Lipofectamine(R) RNAiMAX (Thermo Fisher Scientific Inc.), Lipofectamine(R) MessengerMAX (Thermo Fisher Scientific Inc.), Lipofectamine(R) 2000, Lipofectamine(R) 3000, Neon Transfection System (Thermo Fisher Scientific Inc.), Stemfect RNA Transfection Reagent (STEMGENT), NextFect(R) RNA Transfection Reagent (Bioo Scientific Inc.), Amaxa(R) Human T Cell Nucleofector(R) Kit (Lonza Japan Ltd., VAPA-1002), Amaxa(R) Human CD34 Cell Nucleofector(R) Kit (Lonza Japan Ltd., VAPA-1003) and ReproRNA(R) Transfection Reagent (STEMCELL Technologies Inc.) can be used as RNA lipid transfection reagents.
[0400] The number of blood cells used for lipid transfection with reprogramming factor RNA is, for example, 1 to 1×10 8 cells, 1×10 4 cells to 5×10 6 cells or 5×10 5 cells to 5×10 6 cells. The amount of reprogramming factor RNA used for lipid transfection per milliliter of culture medium is, for example, 5 ng to 50 μg, 50 ng to 10 μg, or 600 ng to 3 μg each time. The amount of lipid transfection reagent used for lipid transfection is, for example, 0.1 μL to 500 μL, 1 μL to 100 μL, or 1 μL to 40 μL each time. Lipofection with reprogramming factors is performed for 0.1 hour or longer and 24 hours or less, 2 hours or longer and 21 hours or less, 12 hours and 30 minutes or longer and 18 hours and 30 minutes or less, or 18 hours each time. For example, when a 12-well plate is used and the number of cells is 4×10 5 When using 6 μL RNAiMAX or 3 μL MessengerMAX.
[0401] Lipofection for reprogramming is repeated, for example, once every two days or once every day or once every five days or longer and nine days or shorter, once every six days or longer and eight days or shorter, or once every seven days. However, when mRNA is a replicating RNA, a single lipofection may be performed. The culture medium used in the lipofection with the reprogramming factor RNA is, for example, a low serum culture medium, such as Opti-MEM (Gibco).
[0402] For example, by analyzing whether at least one surface marker selected from TRA-1-60, TRA-1-81, SSEA-1 and SSEA5 is positive using a flow cytometer, it is confirmed whether induced pluripotent stem cells are induced from blood cells or whether blood cells are reprogrammed into induced pluripotent stem cells, wherein these markers are cell surface markers indicating undifferentiation. TRA-1-60 is an antigen specific to iPS / ES cells and is not detected in somatic cells. Since iPS cells can only be obtained from TRA-1-60 positive fragments, TRA-1-60 positive cells are considered as one of iPS cells.
[0403] In the above-mentioned method for producing induced pluripotent stem cells according to an embodiment of the present invention, induced pluripotent stem cells are produced by transferring RNA that allows expression of reprogramming factors into somatic cells such as blood cells and expressing reprogramming factors. Therefore, it is possible to produce induced pluripotent stem cells without integrating reprogramming factors into the DNA of somatic cells.
[0404] In the conventional method for producing induced pluripotent stem cells, reprogramming factors are inserted into somatic cell DNA. This damages the genome and triggers the tumorigenesis of cells. In contrast, in the method for producing induced pluripotent stem cells according to an embodiment of the present invention, because RNA encoding reprogramming factors is used, it is possible to produce induced pluripotent stem cells without inserting genes into the genome, and there is no possibility of related tumorigenesis. Therefore, the induced pluripotent stem cells produced by the production method according to an embodiment of the present invention make it possible to meet the manufacturing practice of good clinically available cells.
[0405] In the conventional method of using retrovirus or slow virus to produce induced pluripotent stem cells, the virus is retained in the produced induced pluripotent stem cells. In contrast, in the method for producing induced pluripotent stem cells according to an embodiment of the present invention, since the reprogramming factor RNA is transferred by lipid transfection, viruses are not required. Therefore, there is no virus in the produced induced pluripotent stem cells. Similarly, in this regard, the induced pluripotent stem cells produced by the production method according to an embodiment of the present invention make it possible to meet the manufacturing practice of good clinically available cells.
[0406] Conventional methods for producing induced pluripotent stem cells using electroporation greatly damage cells before induction and destroy a large number of cells. In contrast, the lipid transfection used in the method for producing induced pluripotent stem cells according to an embodiment of the present invention has almost no damage to cells before induction and does not destroy a large number of cells. In addition, lipid transfection does not require expensive equipment and is carried out through a simple process.
[0407] In order to produce induced pluripotent stem cells from fibroblasts, it is necessary to collect skin cells through highly invasive biopsy. In contrast, the method for producing induced pluripotent stem cells according to an embodiment of the present invention makes it possible to collect blood cells through low-invasive blood collection. Generally, a sufficient number of blood cells required for the production of induced pluripotent stem cells can be obtained from blood collection. Therefore, unlike fibroblasts, blood cells do not have to proliferate before inducing induced pluripotent stem cells. In addition, blood cells do not have the risk of DNA damage that may occur during proliferation culture. In addition, unlike skin cells, blood cells can be collected without being excreted from the body. Therefore, induced pluripotent stem cells can be induced from blood cells obtained in the blood collection stage in a clean, sealed system. In this regard, blood cells are also suitable for clinical use.
[0408] (Example 13)
[0409] (preparation)
[0410] Human blood cells were obtained from healthy adult males. In addition, modified mRNA (TriLink BioTechnologies Co., Ltd.), non-adherent culture dishes, 15 mL tubes, 50 mL tubes, Ficoll, flow cytometer (Becton, Dickinson and Company), anti-CD34 antibody (Miltenyi Biotec K.K.), anti-CD3 antibody (Miltenyi Biotec KK), MACS (R) buffer (Miltenyi Biotec KK), T cell culture medium, low serum medium (Opti-MEM, Gibco), siRNA transfer reagent (Lipofectamine (R) RNAiMAX, Thermo Fisher Scientific Co., Ltd.) and anti-TRA-1-60 antibody (Becton, Dickinson and Company) were prepared.
[0411] The T cell (CD3 positive cell) culture medium is a mixed solution of the following A culture medium and B culture medium. A culture medium is a mixed solution of 15 mL of X vivo-10 (Lonza Japan Co., Ltd., 04-743Q) and IL-2 (10 μg / mL). B culture medium is prepared by mixing X vivo-10 and 50 μL of Dynabeads CD3 / CD28 (Life Technologies Co., Ltd., 111-31D) in a 1.5 mL tube, vortexing the tube for 5 seconds, then rotating the tube, standing the tube on DynaMag-2 (Thermo Fisher Scientific Co., Ltd.), and removing the supernatant after standing for 1 minute.
[0412] To 10 mL of serum-free culture medium (StemSpan H3000, STEMCELL Technologies, Inc.), 10 μL of IL-6 (100 μg / mL), 10 μL of SCF (300 μg / mL), 10 μL of TPO (300 μg / mL), 10 μL of Flt3 ligand (300 μg / mL) and 10 μL of IL-3 (10 μg / mL) were added to prepare a blood cell culture medium (hematopoietic stem / progenitor cell culture medium).
[0413] In addition, a solution containing OCT3 / 4mRNA, a solution containing SOX2mRNA, a solution containing KLF4mRNA, a solution containing c-MYCmRNA, a solution containing LIN28AmRNA and a solution containing green fluorescent protein (GFP)mRNA were prepared so that their corresponding concentrations were 100ng / μL. Next, 385μL of a solution containing OCT3 / 4mRNA, 119μL of a solution containing SOX2mRNA, 156μL of a solution containing KLF4mRNA, 148μL of a solution containing c-MYCmRNA, 83μL of a solution containing LIN28AmRNA and 110μL of a solution containing GFPmRNA were mixed to obtain a reprogramming factor mixed solution. The obtained reprogramming factor mixed solution was distributed to 1.5mL of an RNase-free tube (Eppendorf tube, Eppendorf AG) at 50μL / tube and stored in a refrigerator at -80°C.
[0414] (Preparation of Monocytes)
[0415] The centrifuge is set to 18 ° C. Collect 5mL to 50mL of blood, and EDTA is added to the blood, then gently mixed. Human lymphocyte separation medium (Ficoll-Paque PREMIUM, GE Healthcare Japan Co., Ltd.) is distributed to two 15mL tubes with 5mL / tube. 5mL of PBS is added to the blood for dilution, and 5mL of the diluted blood is layered on the human lymphocyte separation medium in each tube. At this time, the diluted blood is slowly added to the culture medium so that the blood flows downward along the tube wall without interfering with the interface.
[0416] The solution in the tube was centrifuged at 400 × g for 30 minutes at 18 ° C. In this operation, both acceleration and deceleration were performed slowly. After centrifugation, a white turbid middle layer appeared in the tube. The white turbid middle layer contained mononuclear cells. The white turbid middle layer in the tube was gradually recovered with a pipette and transferred to a new 15 mL tube. In this operation, be careful to avoid sucking out the lower layer. About 1 mL of the white turbid middle layer can be recovered from one tube. The middle layers from the two tubes were transferred to one tube together.
[0417] 12 mL of PBS was added to the recovered mononuclear cells, and the solution was further centrifuged at 200 × g for 10 minutes at 18°C. Then, the supernatant of the solution was removed using an aspirator, and the mononuclear cells were suspended by adding 3 mL of a serum-free hematopoietic cell culture medium (X-VIVO (R) 10, Lonza Japan Co., Ltd.) having a known composition to obtain a mononuclear cell suspension. A 10 μL aliquot of the mononuclear cell suspension was stained with Trypan Blue and counted using a hemocytometer.
[0418] (Isolation of CD34 or CD3 positive cells)
[0419] Make 1×10 7 Each monocyte was reacted with an anti-CD34 antibody or an anti-CD3 antibody in a 100 μL solution at 4°C for 15 minutes. After the reaction, 5 mL of MACS (R) buffer (Miltenyi Biotec KK) was added to the solution, and the mixed solution was centrifuged at 270 g. After centrifugation, the supernatant was removed, and 1 mL of MACS buffer was added to the cells. Then, CD34-positive cells or CD3-positive cells in monocytes were separated using a separation procedure of an automatic magnetic cell separation device (autoMACS, Miltenyi Biotec KK).
[0420] (Cultivation of isolated cells)
[0421] 5×10 6The isolated monocytes were suspended in 1 mL of T cell culture medium or hematopoietic stem / progenitor cell culture medium, seeded into 12-well plates and cultured. The culture conditions included 5% CO 2 concentration, 19% oxygen concentration and 37°C temperature.
[0422] (Lipofection of reprogramming factors)
[0423] 100 μL of low serum medium (Opti-MEM(R), Gibco) and 25 μL of reprogramming factor mixed solution were mixed to prepare a first mixed solution. In addition, 112.5 μL of low serum medium (Opti-MEM(R), Gibco) and 12.5 μL of siRNA transfer reagent (Lipofectamine(R) RNAiMAX, Thermo Fisher Scientific Co., Ltd.) were mixed to prepare a second mixed solution. Next, the first mixed solution and the second mixed solution were mixed and allowed to stand at room temperature for 15 minutes to prepare a lipid transfection reaction solution.
[0424] During the culture, the obtained lipid transfection reaction solution was slowly added to a 12-well plate containing monocytes at 60 μL / well, and then the monocytes were cultured at 37° C. in a feeder-free manner for 18 hours.
[0425] The culture conditions included 5% CO 2 concentration, 19% oxygen concentration and 37°C temperature. When the lipid transfection reaction solution was added, the density of monocytes was 3×10 6 Cells. After 18 hours, the monocytes were recovered in a 15 mL tube and centrifuged at 300 g, followed by removal of the supernatant. Then, 1.25 mL of blood cell culture medium for CD34 was added to the 15 mL tube. The monocyte suspension was returned to the same 12-well plate as above. The monocytes were cultured overnight at 37°C without feeder cells.
[0426] The culture conditions included 5% CO 2 concentration and 19% oxygen concentration. These steps were repeated every two days for seven days.
[0427] (Confirm GFP expression)
[0428] On day 7 after the start of lipid transfection, the cell density for a total of four lipid transfections was 3 × 10 6 cells. Take an aliquot from the 12-well plate and confirm GFP expression under a fluorescence microscope. Fig.35 As shown, the expression of GFP was confirmed. Based on these results, it was confirmed that the protein was synthesized from the mRNA carried by the monocytes transfected with the mRNA.
[0429] (Confirmation of TRA-1-60 expression)
[0430] On the 7th day after the start of lipid transfection, an aliquot of the cells was taken out from the 12-well plate, and the cells thus taken out were stained with an antibody labeled with allophycocyanin (APC) fluorescent dye against TRA-1-60 (a surface antigen specifically expressed on cells in which reprogramming has begun). Then, the percentage of TRA-1-60-positive cells was confirmed using a fluorescence activated cell sorter (FACS(R), Becton, Dickinson and Company) to confirm that reprogramming had begun in the cells so that iPS cell genes were expressed to generate iPS cells.
[0431] like Fig.36 As shown, a dot plot is made with the fluorescence intensity of the autofluorescence intensity on the x-axis relative to the fluorescence intensity of the fluorescently labeled anti-TRA-1-60 antibody on the y-axis. No TRA-1-60 positive cells were detected in the negative control that did not carry the gene. On the contrary, TRA-1-60 positive cells were detected in experiments 1, 2, and 3. Experiment 1 describes the results of inducing iPS cells from all monocytes that were not separated based on the marker. Experiment 2 describes the results of inducing iPS cells from cells separated from CD3 positive. Experiment 3 describes the results of inducing iPS cells from cells separated from CD34 positive. These results indicate that it is possible to induce iPS cells by transferring reprogramming factors to hemogenic cells using lipid transfection with reprogramming factor RNA.
[0432] (Sixth Embodiment)
[0433] The method for producing somatic cells from animal cells according to an embodiment of the present invention includes: preparing animal cells; and transferring inducer ribonucleic acid (RNA) into the animal cells by lipofection to differentiate the animal cells into somatic cells.
[0434] Animal cells include stem cells. Both induced pluripotent stem cells (iPS cells) and embryonic stem cells (ES cells) can be used as stem cells. Animal cells can be human fibroblasts or human blood cells.
[0435] Stem cells can be cultured using a culture medium such as Primate ES cell medium, mTeSR1, TeSR2, or TeSRE8 (STEMCELL Technologies, Inc.).
[0436] The culture medium for culturing stem cells may contain a gel. The gel may contain at least one polymer compound selected from the group consisting of deacylated gellan gum, gellan gum, hyaluronic acid, rhamnose gum, diutan gum, xanthan gum, carrageenan, fucoidan, pectin, pectic acid, pectinic acid, heparan sulfate, heparan, heparan sulfate, keratan sulfate, chondroitin sulfate, dermatan sulfate, rhamnan sulfate and salts thereof. The gel culture medium may contain methylcellulose. The methylcellulose contained therein inhibits aggregation between cells.
[0437] The gel may be a thermosensitive gel. The thermosensitive gel may be at least one selected from the following: poly(glycerol monomethacrylate) (PGMA), poly(2-hydroxypropyl methacrylate) (PHPMA), poly(N-isopropylacrylamide) (PNIPAM), amine-terminated, carboxylic acid-terminated, maleimide-terminated, N-hydroxysuccinimide (NHS) ester-terminated, triethoxysilane-terminated, poly(N-isopropylacrylamide-co-acrylamide), poly(N-isopropylacrylamide-co-acrylic acid), poly(N-isopropylacrylamide-co-butyl acrylate), poly(N-isopropylacrylamide-co-methacrylic acid), poly(N-isopropylacrylamide-co-methacrylic acid-co-octadecyl acrylate) and N-isopropylacrylamide.
[0438] The medium for culturing stem cells may contain at least one substance selected from the group consisting of cadherin, laminin, fibronectin, and vitronectin.
[0439] The somatic cells produced from animal cells are, for example, neuronal cells, but somatic cells are not limited thereto. For example, somatic cells such as cardiomyocytes, hepatocytes, retinal cells, corneal cells and blood cells can be produced. In the case of producing neuronal cells, the inducer RNA to be transferred into the animal cells includes, for example, neurogenin 2 (Ngn2) mRNA. Ngn2 is a conversion protein necessary for differentiation into neuronal cells. The inducer RNA may include mRNA corresponding to a drug resistance gene. The drug is, for example, an antibiotic, such as puromycin, neomycin, blasticidin, G418, hygromycin or bleomycin. Cells carrying the inducer RNA exhibit drug resistance.
[0440] Each mRNA contained in the inducer RNA may be modified with at least one selected from the group consisting of pseudouridine (Ψ), 5-methyluridine (5meU), N1-methylpseudouridine (me1Ψ), 5-methoxyuridine (5moU), 5-hydroxymethyluridine (5hmU), 5-formyluridine (5fU), 5-carboxymethyluridine (5camU), thioguanosine (thG), N4-methylcytidine (me4C), 5-methylcytidine (5hC), 5-methylur ... (m5C), 5-methoxycytidine (5moC), 5-hydroxymethylcytidine (5hmC), 5-hydroxycytidine (5hoC), 5-formylcytidine (5fC), 5-carboxycytidine (5caC), N6-methyl-2-aminoadenosine (m6DAP), diaminopurine (DAP), 5-methyluridine (m5U), 2'-O-methyluridine (Um or m2'-OU), 2-thiouridine (s2U) and N6-methyladenosine (m6A).
[0441] mRNA can be polyadenylated. mRNA can be prepared by polyadenylation of in vitro transcribed (IVT) RNA. mRNA can be polyadenylated during IVT by using a DNA template encoding a poly(A) tail. mRNA can be capped. To maximize expression efficiency in cells, the vast majority of mRNA molecules can contain a cap.
[0442] mRNA may have a 5' cap [m7G(5')ppp(5')G] structure. This sequence stabilizes mRNA and promotes mRNA transcription. From mRNA with 5' triphosphate, the 5' triphosphate can be removed by dephosphorylation. mRNA may have [3'O-Me-m7G(5')PPP(5')G] as an anti-reverse transcription cap analog (ARCA). ARCA is a sequence inserted upstream of the transcription start point and doubles the mRNA transcription efficiency. mRNA may have a poly (A) tail.
[0443] Inducer RNA includes, for example, Ngn2-T2A-Puro mRNA (TriLink BioTechnologies, Inc., RNA corresponding to the DNA described in SEQ ID NO: 1). Cells transfected with Ngn2-T2A-Puro mRNA (TriLink BioTechnologies, Inc.) produce neurogenin 2 (Ngn2) and also exhibit puromycin resistance. mRNA can be capped with an anti-reverse transcription cap analog (ARCA), polyadenylated, and substituted with 5-methylcytidine and pseudouridine. 5-methylcytidine and pseudouridine reduce the ability of antibodies to recognize mRNA. RNA corresponding to the DNA described in SEQ ID NO: 2 can be used. The DNA described in SEQ ID NO: 2 is derived from the DNA of SEQ ID NO: 1 by removing the xbal restriction site.
[0444] The inducer RNA is transferred into animal cells by lipofection. Lipofection is a method involving the formation of a complex of nucleic acid (negatively charged substance) and positively charged lipids through electrical interaction, and the entry of the complex into cells through endocytosis or membrane fusion. Lipofection has advantages such as little cell damage, excellent transfer efficiency, easy operation, and short duration.
[0445] For example, Lipofectamine MessengerMAX (R) is used as a lipid transfection reagent in lipid transfection of inducer RNA. Alternatively, for example, Lipofectamine (R) RNAiMAX (Thermo Fisher Scientific Co., Ltd.), Lipofectamine (R) 2000, Lipofectamine (R) 3000, Neon transfection system (Thermo Fisher Scientific Co., Ltd.), Stemfect RNA transfection reagent (STEMGENT), NextFect (R) RNA transfection reagent (Bioo Scientific Co., Ltd.), Amaxa (R) Human T Cell Nucleofector (R) Kit (Lonza Japan Co., Ltd., VAPA-1002), Amaxa (R) Human CD34 Cell Nucleofector (R) Kit (Lonza Japan Co., Ltd., VAPA-1003) and ReproRNA (R) Transfection Reagent (STEMCELL Technologies Co., Ltd.) can be used as lipid transfection reagents.
[0446] When using, for example, a 12-well plate, the number of cells used for lipid transfection with inducer RNA is 1 x 10 per well. 4 Up to 1×10 8 , 5×10 4 Up to 1×10 6 , or 1×10 5 Up to 5×10 5 The bottom area of a hole is 4 cm 2 The amount of inducer RNA used for lipid transfection with inducer RNA is 200 ng to 5000 ng, 400 ng to 2000 ng, or 500 ng to 1000 ng each time. The amount of lipid transfection reagent used for lipid transfection with inducer RNA is 0.1 μL to 100 μL, 1 μL to 50 μL, or 1.5 μL to 10 μL.
[0447] The culture medium used for lipid transfection with inducer RNA is, for example, a low serum culture medium, such as Opti-MEM(R) (Gibco). The culture medium used during lipid transfection of inducer RNA and before or after such lipid transfection may contain B18R protein. B18R protein reduces the innate antiviral response of cells. B18R protein can be used to inhibit cell death caused by immune responses associated with RNA insertion into cells. However, because the method for producing somatic cells from animal cells according to the present embodiment differentiates animal cells into somatic cells in a short period of time, the culture medium may not contain B18R protein or may contain B18R protein at a dilution concentration of 0.01% to 1%.
[0448] Within ten days, nine days, eight days or seven days after lipid transfection of the self-inducer RNA, the animal cells differentiate into somatic cells. When the somatic cells to be produced are neuronal cells, whether they differentiate into neuronal cells is confirmed based on whether they are positive for Ngn2, β-III tubulin, MAP2, PsA-NCAM or vGlu. Ngn2 is a conversion protein required for differentiation into neuronal cells. β-III tubulin, MAP2, PsA-NCAM and vGlu are markers for marking neuronal cells and are constituent proteins of microtubules in neurites.
[0449] When the inducer RNA comprises an mRNA corresponding to a drug resistance gene, cells exhibiting drug resistance can be selected after lipofection. When the inducer RNA comprises, for example, an mRNA corresponding to a puromycin resistance gene, cells other than cells carrying the inducer RNA can be destroyed by exposing the lipofected cells to puromycin to select cells carrying the inducer RNA. The inducer RNA may comprise an mRNA corresponding to a gene of any antibiotic selected from neomycin, blasticidin, G418, hygromycin, bleomycin, etc. as the mRNA corresponding to the drug resistance gene.
[0450] The method for producing somatic cells from animal cells according to the above-mentioned embodiment of the present invention makes it possible to efficiently produce somatic cells such as neuronal cells by expressing RNA encoding specific genes in animal cells including iPS / ES cells while damaging genes in animal cells including iPS / ES cells.
[0451] The method of producing somatic cells from iPS / ES cells etc. using hormones or chemicals requires a very long time to produce somatic cells. In contrast, the method of producing somatic cells from animal cells according to an embodiment of the present invention has the potential to produce somatic cells in a very short time.
[0452] In the method of producing somatic cells from animal cells including iPS / ES cells using hormones or chemicals, only some of the animal cells including iPS / ES cells are converted into somatic cells of interest. In contrast, the method of producing somatic cells from animal cells according to an embodiment of the present invention converts 90% or more of the cells into somatic cells of interest by RNA transfer.
[0453] In the method of producing somatic cells from iPS / ES cells etc. using hormones or chemicals, even if the same protocol is used, it leads to differences between colonies, so that some colonies become somatic cells of interest while other colonies remain unchanged. In contrast, the method of producing somatic cells from animal cells according to an embodiment of the present invention has the potential to achieve high-efficiency induction differentiation of multiple colonies.
[0454] In the case of using cytokines, etc. to induce the differentiation of undifferentiated cell groups such as ES / iPS cells to produce cells for transplantation, it is possible that undifferentiated cells remain in the cells for transplantation. Such residual undifferentiated cells have the risk of forming teratomas, etc. due to their own cell division and proliferation at the transplantation site. In contrast, the method for producing somatic cells from animal cells according to an embodiment of the present invention is likely to select cells carrying inducer RNA based on drugs, because drug resistance genes can be co-expressed with them. Therefore, the cells produced by the method of the present invention can avoid the risks of undifferentiated cell contamination and teratoma formation, etc., and are therefore suitable for medical transplantation.
[0455] In the method for producing somatic cells from animal cells of the embodiment of the present invention using the lipid transfection method, no virus is used. Therefore, the genes of the stem cells are not damaged, and the produced somatic cells have no associated tumor risk and can be used for clinical treatment.
[0456] The method of using virus to produce somatic cells from stem cells requires Escherichia coli to produce and propagate viral vectors. However, cells produced by transferring substances produced using non-human organisms are not suitable for clinical applications. In contrast, the method of generating somatic cells from animal cells according to an embodiment of the present invention can transfer RNA to animal cells including iPS / ES cells by using lipid transfection. Because RNA is a chemical substance and can be synthesized artificially, RNA can be manufactured without the use of organisms such as Escherichia coli and is suitable for clinical applications.
[0457] For example, iPS cells are produced from blood cells in a clean environment of a completely sealed system, and then somatic cells are produced from iPS cells in a clean environment of a completely sealed system. In this case, it is possible to produce cleaner and safer somatic cells.
[0458] In addition, the method for producing somatic cells from animal cells according to an embodiment of the present invention makes it possible to produce somatic cells in a short time. Therefore, for example, it is not necessary to use B18R that suppresses cell death caused by immune response associated with mRNA insertion. Even if such a substance is used, its extremely dilute concentration is possible.
[0459] (Example 14)
[0460] A 12-well culture dish coated with a soluble basement membrane preparation (Matrigel, Corning Co., Ltd.) was prepared. A feeder-free cell culture medium (mTeSR(R)1, STEMCELL Technologies, Inc.) containing a ROCK (Rho-associated coiled-coil kinase / Rho-binding kinase) inhibitor (Selleck Chemicals) at a concentration of 10 umol / L was placed in each well. The ROCK inhibitor inhibits cell death.
[0461] iPS cells were dispersed in a detachment / separation / dispersion solution for tissue / culture cells (Accutase, Innovative Cell Technologies, Inc.) and seeded into a 12-well culture dish. The cells to be transfected were plated at 4×10 5 The bottom area of a well is 4 cm 2 Untransfected control cells were plated at 2×10 5 The cells were then inoculated at a density of 10 cells / mL. The cells were then cultured in feeder-free medium for 24 hours. The temperature was 37°C and CO 2 The concentration is 5% and the oxygen concentration is 25% or less.
[0462] 1.25 mL of xeno-free medium (Pluriton, Stemgent Co., Ltd.), 0.5 μL of Pluriton supplement (Stemgent Co., Ltd.) and 2 μL of a solution containing 100 ng / μL of B18R recombinant protein (eBioscience) were mixed to prepare a transfection medium. Prior to transfection, the feeder-free medium in each well was replaced with a transfection medium, in which the cells were cultured at 37° C. for 2 hours.
[0463] Green fluorescent protein (GFP) mRNA was prepared (TriLink BioTechnologies, Inc.) The mRNA was capped with anti-retroviral cap analog (ARCA), polyadenylated, and substituted with 5-methylcytidine and pseudouridine.
[0464] Prepare 1.5 mL microcentrifuge tubes A and 1.5 mL microcentrifuge tubes B respectively to correspond to the number of wells.
[0465] 62.5 μL of low serum medium (Opti-MEM, Gibco) was placed in each tube A, and then 1.875 μL of a reagent for mRNA transfer (Lipofectamine MessengerMAX, Invitrogen Co., Ltd.) was added thereto and mixed well to prepare a first reaction solution. Then, tube A was tapped at room temperature for 10 minutes to mix the first reaction solution.
[0466] 62.5 μL of a low-serum medium (Opti-MEM(R), Gibco) was placed in each tube B, 500 ng of GFP mRNA (TriLink BioTechnologies, Inc.) was added thereto and mixed well to prepare a second reaction solution.
[0467] The second reaction solution was added to the first reaction solution in tube A to prepare a mixed reaction solution. Then, tube A was tapped at room temperature for 5 minutes to allow liposome formation. Next, the mixed reaction solution was added to each well and left to stand overnight at 37°C. Thus, 500 ng of GFP mRNA was added to each well.
[0468] The next day, observe the cells under a fluorescence microscope. Fig.37 and Fig.38 As shown, cells transfected with MessengerMAX produced the most intense color. Fig.39As shown, cells transfected with MessengerMAX also showed the highest survival rate. This revealed that MessengerMAX was best suited for mRNA transfer. These results suggest that it is possible to express proteins in iPS cells by using lipid transfection reagents and RNA for mRNA transfer.
[0469] (Example 15)
[0470] A 12-well culture dish coated with a soluble basement membrane preparation (Matrigel, Corning Co., Ltd.) was prepared. A feeder-free cell culture medium (mTeSR(R)1, STEMCELL Technologies, Inc.) containing a ROCK (Rho-associated coiled-coil kinase / Rho-binding kinase) inhibitor (Selleck Chemicals) at a concentration of 10 μmol / L was placed in each well. The ROCK inhibitor inhibits cell death.
[0471] iPS cells were dispersed in a detachment / separation / dispersion solution for tissue / culture cells (Accutase, Innovative Cell Technologies, Inc.) and seeded into a 12-well culture dish. The cells to be transfected were plated at 4×10 5 Untransfected control cells were seeded at a density of 2×10 cells per well. 5 Then, the cells were cultured in feeder-free medium for 24 hours.
[0472] 1.25 mL of xeno-free medium (Pluriton, Stemgent Co., Ltd.), 0.5 μL of Pluriton supplement (Stemgent Co., Ltd.) and 2 μL of a solution containing 100 ng / μL of B18R recombinant protein (eBioscience) were mixed to prepare a transfection medium. Prior to transfection, the feeder-free medium in each well was replaced with a transfection medium, in which the cells were cultured at 37° C. for 2 hours.
[0473] Ngn2-T2A-Puro mRNA (TriLink BioTechnologies, Inc.) and green fluorescent protein (GFP) mRNA (TriLink BioTechnologies, Inc.) were prepared. Each mRNA was capped with an anti-reverse transcription cap analog (ARCA), polyadenylated, and substituted with 5-methylcytidine and pseudouridine. In addition, the mRNA was purified by a silica membrane and prepared into a sodium citrate (pH 6) solution (as a solvent) containing 1 mmol / L together with a reagent for mRNA transfer (Lipofectamine MessengerMAX, Invitrogen, Inc.). 1.5 mL microcentrifuge tube A and 1.5 mL microcentrifuge tube B were prepared respectively to correspond to the number of wells.
[0474] 62.5 μL of low serum medium (Opti-MEM (R), Gibco) was placed in each tube A, and then 1.875 μL of a reagent for mRNA transfer (Lipofectamine MessengerMAX (R), Invitrogen Co., Ltd.) was added thereto and mixed well to prepare a first reaction solution. Then, tube A was tapped at room temperature for 10 minutes to mix the first reaction solution.
[0475] 62.5 μL of low serum medium (Opti-MEM(R), Gibco) was placed in each tube B, and then 500 ng of Ngn2-T2A-Puro mRNA (TriLink BioTechnologies, Inc.) and 1500 ng of GFP mRNA (TriLink BioTechnologies, Inc.) were added thereto and mixed well to prepare a second reaction solution.
[0476] The second reaction solution was added to the first reaction solution in tube A to prepare a mixed reaction solution. Then, tube A was tapped at room temperature for 5 minutes to allow liposome formation. Next, the mixed reaction solution was added to each well and left to stand overnight at 37°C. Thus, 500 ng of Ngn2 mRNA and 100 ng of GFP mRNA were added to each well.
[0477] like Fig.40 As shown by observing cells one day after mRNA transfer, cells transfected with MessengerMAX produced the most intense color.
[0478] Then, the medium was completely replaced with a neural differentiation medium (N2 / DMEM / F12 / NEAA, Invitrogen Co., Ltd.) containing a ROCK inhibitor (Selleck Chemicals) at a concentration of 10 μmol / L and an antibiotic (puromycin) at a concentration of 1 mg / L every day for two days to select mRNA transfected cells. On day 3, the medium was replaced with a neural differentiation medium (N2 / DMEM / F12 / NEAA, Invitrogen Co., Ltd.) containing a solution of B18R recombinant protein at a concentration of 200 ng / mL (eBioscience). Then, the medium was replaced halfway with the same medium as above each time until day 7.
[0479] On the 7th day, the culture medium was removed from each well and the wells were washed with 1 mL of PBS. Then, 4% PFA was placed therein and reacted with the cells at 4 ° C for 15 minutes to fix. Then, after washing twice with PBS, each primary antibody was diluted with a PBS solution containing 5% CCS and 0.1% Triton and added at 500 μL / well. The primary antibodies used were rabbit anti-human Tuj1 antibody (BioLegend 845501) and mouse anti-rat and human Ngn2 antibody (R&D Systems Co., Ltd.). Rabbit anti-human Tuj1 antibody (BioLegend 845501) was diluted 1 / 1000 with buffer, or mouse anti-rat and human Ngn2 antibody (R&D Systems Co., Ltd.) was diluted 1 / 75 with buffer, and DAPI was diluted 1 / 10000 with buffer. These dilutions were added to each well and reacted at room temperature for 1 hour. Anti-Tuj1 antibody is an antibody against β-III tubulin.
[0480] After reacting at room temperature for 1 hour, 1 mL of PBS was added to each well and fully diffused in the well, and then the PBS was discarded. PBS was added again and then discarded. A permeabilization buffer containing a secondary antibody containing a 1 / 1000 dilution of donkey anti-mouse IgG (H + L) secondary antibody-Alexa Fluor (R) 555 complex (Thermo Fisher Scientific, Inc.) or a 1 / 1000 dilution of donkey anti-rabbit IgG (H + L) secondary antibody-Alexa Fluor (R) 647 complex (Thermo Fisher Scientific, Inc.) was added at 500 μL / well and allowed to react at room temperature for 30 minutes.
[0481] After reacting at room temperature for 30 minutes, the cells were washed twice with PBS and observed under a fluorescence microscope to count the fluorescent cells.
[0482] Fig.41 These are photographs of cells taken when observed under a fluorescence microscope, wherein the cells were cultured for 2 days after Ngn2-T2A-Puro mRNA was transferred by lipofection and then puromycin was added, further cultured for 5 days without the addition of puromycin, and stained with Tujl. Fig.42 The percentage of TUJ-1-positive cells on day 7 among cells transfected with Ngn2-T2A-Puro mRNA using each transfection reagent by the above-mentioned procedure is shown. It was found that MessengerMAX had an ability to convert iPS cells into neuronal cells four times or more higher than RNAiMAX or Stemfect.
[0483] Fig.43 Shown are photographs of cells taken under fluorescence microscope observation, wherein the cells were cultured for 6 days after transfer of Ngn2-T2A-Puro mRNA by triple lipofection and subsequent addition of puromycin, further cultured for 16 days without addition of puromycin, and stained with MAP2 (Sigma Cat#M4403) and vGlut (Synaptic Systems Cat#135302).
[0484] (Example 16)
[0485] A 12-well culture dish coated with a soluble basement membrane preparation (Matrigel, Corning Inc.) was prepared, and a feeder-free cell culture medium (mTeSR(R)1, STEMCELL Technologies Inc.) containing a ROCK (Rho-associated coiled-coil kinase / Rho-binding kinase) inhibitor (Selleck Chemicals) at a concentration of 10 μmol was placed in each well.
[0486] iPS cells were dispersed in a detachment / separation / dispersion solution for tissue / culture cells (Accutase, Innovative Cell Technologies, Inc.) and seeded into a 12-well culture dish. The cells to be transfected were plated at 4×10 5 Untransfected control cells were seeded at a density of 1×10 cells per well. 5 The cells were then inoculated at a density of 10 cells / mL. The cells were then cultured in feeder-free medium for 24 hours. The temperature was 37°C and CO 2 The concentration is 5% and the oxygen concentration is 25% or less.
[0487] 1.25 mL of xeno-free medium (Pluriton, Stemgent Co., Ltd.), 0.5 μL of Pluriton supplement (Stemgent Co., Ltd.) and 2 μL of a solution containing a B18R recombinant protein at a concentration of 100 ng / μL (eBioscience) were mixed to prepare a transfection medium with B18R. In addition, 1.25 mL of xeno-free medium (Pluriton, Stemgent Co., Ltd.) and 0.5 μL of Pluriton supplement (Stemgent Co., Ltd.) were mixed to prepare a transfection medium without B18R.
[0488] Prior to transfection, the feeder-free medium in each well was replaced with a transfection medium containing B18R or a transfection medium not containing B18R, in which the cells were cultured at 37°C for 2 hours.
[0489] Ngn2-T2A-Puro mRNA (TriLink BioTechnologies, Inc.) and GFP mRNA (TriLink BioTechnologies, Inc.) were prepared. The mRNA was capped with anti-reversal cap analog (ARCA), polyadenylated, and substituted with 5-methylcytidine and pseudouridine.
[0490] Prepare 1.5 mL microcentrifuge tubes A and 1.5 mL microcentrifuge tubes B respectively to correspond to the number of wells.
[0491] 62.5 μL of low serum medium (Opti-MEM, Gibco) was placed in each tube A, 1.875 μL of reagent for mRNA transfer (Lipofectamine MessengerMAX, Invitrogen Co., Ltd.) was added thereto, and mixed well to prepare a first reaction solution. Then, tube A was tapped at room temperature for 10 minutes to mix the first reaction solution.
[0492] 62.5 μL of low serum medium (Opti-MEM(R), Gibco) was placed in each tube B, and then 500 ng of Ngn2-T2A-Puro mRNA (TriLink BioTechnologies, Inc.) and 100 ng of GFP mRNA (TriLink BioTechnologies, Inc.) were added thereto and mixed well to prepare a second reaction solution.
[0493] The second reaction solution was added to the first reaction solution in tube A to prepare a mixed reaction solution. Then, tube A was tapped at room temperature for 5 minutes to allow liposomes to form. Next, the mixed reaction solution was added to each well and left to stand overnight at 37°C. Thus, 500 ng of Ngn2 mRNA and 100 ng of GFP mRNA were added to each well. Fig.44 As indicated, single-, double-, and triply-transfected samples were prepared.
[0494] Then, the medium was completely replaced with a neural differentiation medium (N2 / DMEM / F12 / NEAA, Invitrogen Co., Ltd.) containing a ROCK inhibitor (Selleck Chemicals) at a concentration of 10 μmol / L and an antibiotic (puromycin) at a concentration of 1 mg / L every day for two days to select mRNA transfected cells. On day 3, the medium was replaced with a neural differentiation medium (N2 / DMEM / F12 / NEAA, Invitrogen Co., Ltd.) containing a solution of B18R recombinant protein at a concentration of 200 ng / mL (eBioscience). Then, the medium was replaced halfway with the same medium as above each time until day 7.
[0495] On the 7th day, the culture medium was removed from each well and the wells were washed with 1 mL of PBS. Then, 4% PFA was placed therein and reacted with the cells at 4°C for 15 minutes for fixation. Then, after washing twice with PBS, each primary antibody was diluted with a permeabilization buffer containing 5% CCS and 0.1% Triton X in PBS and reacted at room temperature for 1 hour. The primary antibodies used were mouse anti-human Tuj1 antibody (BioLegend845501) diluted 1 / 1000 with permeabilization buffer and mouse anti-human Ngn2 antibody (R&D Systems Co., Ltd., MAB3314-SP) diluted 1 / 150 with permeabilization buffer, and DAPI was further added thereto at 1 / 10000.
[0496] After 1 hour, 1 mL of PBS was added to each well and fully diffused in the well, and then the PBS was discarded. PBS was added again and then discarded. A permeabilization buffer containing a secondary antibody containing a 1:1000 dilution of donkey anti-mouse IgG (H+L) secondary antibody-AlexaFluor(R)555 complex (Thermo Fisher Scientific, Inc., A-21428) or a 1:1000 dilution of donkey anti-rabbit IgG (H+L) secondary antibody-Alexa Fluor(R)647 complex (Thermo Fisher Scientific, Inc., A31573) was added at 500 μL / well and allowed to react at room temperature for 30 minutes.
[0497] The cells were washed twice with PBS and observed under a fluorescence microscope to count the fluorescent cells. Fig.45 As shown, cells singly transfected with mRNA hardly expressed GFP on day 9. On the other hand, cells triply transfected with mRNA expressed GFP even on day 9. This revealed that mRNA was degraded in cells and protein expression was transient. Fig.46 Magnified images of cells triply transfected with mRNA expressing GFP at day 7 are shown.
[0498] The above results show that it is possible to induce neuronal cells a few days after iPS cell inoculation and transfection with RNA. The results also show that because neuronal cells can be induced in a short time, the culture medium does not need to contain B18R protein, which is generally used to suppress cell death caused by immune response associated with RNA insertion into cells.
[0499] [reference numerals list]
[0500] 10: Separation device
[0501] 20: Cell solution sending channel before transfer
[0502] 21: Inducer solution delivery mechanism
[0503] 30: Inducer transfer device
[0504] 31: Cell solution sending channel after transfer
[0505] 40: Cell mass production device
[0506] 50: Reprogramming culture device
[0507] 51: Cell cluster solution sending channel
[0508] 60: Split mechanism
[0509] 70: Expansion culture device
[0510] 71: Amplification culture solution sending channel
[0511] 72: Cell cluster solution sending channel
[0512] 80: Split mechanism
[0513] 90: Cell cluster transport mechanism
[0514] 91: Pre-packaged cell channel
[0515] 100: Packaging device
[0516] 110: Cryopreservation fluid delivery agency
[0517] 200: Container
[0518] Sequence Listing
[0519]
[0520]
[0521]
[0522] Sequence Listing <110> Ai Ping Shi Co., Ltd. <120> Method for producing specific somatic cells from animal cells <130> A2479AIP0001-PCT <160> 2 <170> PatentIn version 3.5.1 <210> 1 <211> 1479 <212> DNA <213> Artificial sequence <220> <223> Predisposing factors <400> 1 atggactaca aggacgacga tgacaagttc gtcaaatctg agactctgga gttgaaggag 60 gaagaggagg tactgatgct gctgggctcg gcttccccgg cctcggcgac cctgaccccg 120 atgtcctcca gcgcggacga ggaggaggac gaggagctgc gccggccggg ctccgcgcgt 180 gggcagcgtg gagcggaagc cgggcagggg gtgcagggca gtccggcgtc gggtgccggg 240 ggttgccggc cagggcggct gctgggcctg atgcacgagt gcaagcgtcg cccgtcgcgc 300 tcacgggccg tctcccgagg tgccaagacg gcggagacgg tgcagcgcat caagaagacc 360 cgcaggctca aggccaacaa ccgcgagcgc aaccgcatgc acaacctaaa cgccgcgctg 420 gacgcgctgc gcgaggtgct gcccaccttc cccgaggatg ccaagctcac gaagatcgag 480 acgctgcgct tcgcccacaa ttacatctgg gcgctcaccg agactctgcg cctggcggac 540 cactgcgccg gcgccggtgg cctccagggg gcgctcttca cggaggcggt gctcctgagc 600 ccgggagctg cgctcggcgc cagcggggac agcccttctc caccttcctc ctggagctgc 660 accaacagcc cggcgtcatc ctccaactcc acgtccccat acagctgcac tttatcgccc 720 gctagccccg ggtcagacgt ggactactgg cagcccccac ctccggagaa gcatcgttat 780 gcgcctcacc tgcccctcgc cagggactgt atctctagag agggcagggg aagtcttcta 840 acatgcgggg acgtggagga aaatcccggc ccactcgaga tgaccgagta caagcccacg 900 gtgcgcctcg ccacccgcga cgacgtcccc agggccgtac gcaccctcgc cgccgcgttc 960 gccgactacc ccgccacgcg ccacaccgtc gatccggacc gccacatcga gcgggtcacc 1020 gagctgcaag aactcttcct cacgcgcgtc gggctcgaca tcggcaaggt gtgggtcgcg 1080 gacgacggcg ccgcggtggc ggtctggacc acgccggaga gcgtcgaagc gggggcggtg 1140 ttcgccgaga tcggcccgcg catggccgag ttgagcggtt cccggctggc cgcgcagcaa 1200 cagatggaag gcctcctggc gccgcaccgg cccaaggagc ccgcgtggtt cctggccacc 1260 gtcggcgtct cgcccgacca ccagggcaag ggtctgggca gcgccgtcgt gctccccgga 1320 gtggaggcgg ccgagcgcgc cggggtgccc gccttcctgg agacctccgc gccccgcaac 1380 ctccccttct acgagcggct cggcttcacc gtcaccgccg acgtcgaggt gcccgaagga 1440 ccgcgcacct ggtgcatgac ccgcaagccc ggtgcctga 1479 <210> 2 <211> 1473 <212> DNA <213> Artificial Sequence <220> <223> Inducing factor <400> 2 atggactaca aggacgacga tgacaagttc gtcaaatctg agactctgga gttgaaggag 60 gaagaggagg tactgatgct gctgggctcg gcttccccgg cctcggcgac cctgaccccg 120 atgtcctcca gcgcggacga ggaggaggac gaggagctgc gccggccggg ctccgcgcgt 180 gggcagcgtg gagcggaagc cgggcagggg gtgcagggca gtccggcgtc gggtgccggg 240 ggttgccggc cagggcggct gctgggcctg atgcacgagt gcaagcgtcg cccgtcgcgc 300 tcacgggccg tctcccgagg tgccaagacg gcggagacgg tgcagcgcat caagaagacc 360 cgcaggctca aggccaacaa ccgcgagcgc aaccgcatgc acaacctaaa cgccgcgctg 420 gacgcgctgc gcgaggtgct gcccaccttc cccgaggatg ccaagctcac gaagatcgag 480 acgctgcgct tcgcccacaa ttacatctgg gcgctcaccg agactctgcg cctggcggac 540 cactgcgccg gcgccggtgg cctccagggg gcgctcttca cggaggcggt gctcctgagc 600 ccgggagctg cgctcggcgc cagcggggac agcccttctc caccttcctc ctggagctgc 660 accaacagcc cggcgtcatc ctccaactcc acgtccccat acagctgcac tttatcgccc 720 gctagccccg ggtcagacgt ggactactgg cagcccccac ctccggagaa gcatcgttat 780 gcgcctcacc tgcccctcgc cagggactgt atcgagggca ggggaagtct tctaacatgc 840 ggggacgtgg aggaaaatcc cggcccactc gagatgaccg agtacaagcc cacggtgcgc 900 ctcgccaccc gcgacgacgt ccccagggcc gtacgcaccc tcgccgccgc gttcgccgac 960 taccccgcca cgcgccacac cgtcgatccg gaccgccaca tcgagcgggt caccgagctg 1020 caagaactct tcctcacgcg cgtcgggctc gacatcggca aggtgtgggt cgcggacgac 1080 ggcgccgcgg tggcggtctg gaccacgccg gagagcgtcg aagcggggc ggtgttcgcc 1140 gagatcggcc cgcgcatggc cgagttgagc ggttcccggc tggccgcgca gcaacagatg 1200 gaaggcctcc tggcgccgca ccggcccaag gagcccgcgt ggttcctggc caccgtcggc 1260 gtctcgcccg accaccaggg caagggtctg ggcagcgccg tcgtgctccc cggagtggag 1320 gcggccgagc gcgccggggt gcccgcttc ctggagacct ccgcgccccg caacctcccc 1380 ttctacgagc ggctcggctt caccgtcacc gccgacgtcg aggtgcccga aggaccgcgc 1440 acctggtgca tgacccgcaa gcccggtgcc tga 1473
Claims
1. A method for producing induced pluripotent stem cells, comprising: Preparation of somatic cells; as well as The reprogramming factor RNA is transferred into the somatic cells by lipid transfection. The somatic cell is a blood cell, The blood cells are mononuclear cells, The reprogramming factor RNA includes Oct3 / 4 mRNA, Sox2 mRNA, Klf4 mRNA, c-Myc mRNA and LIN28A mRNA, or includes Oct3 / 4 mRNA, Sox2 mRNA, Klf4 mRNA, c-Myc mRNA and LIN28B mRNA. 2 . The method for producing induced pluripotent stem cells according to claim 1 , wherein the mononuclear cells are CD34 positive. 3 . The method for producing induced pluripotent stem cells according to claim 1 , wherein the mononuclear cells are mononuclear cells isolated under the condition that the cells are CD34 positive. The method for producing induced pluripotent stem cells according to claim 1 , wherein the mononuclear cells are CD3 positive. 5 . The method for producing induced pluripotent stem cells according to claim 1 , wherein the mononuclear cells are mononuclear cells isolated under the condition that the cells are CD3-positive. 6 . The method for producing induced pluripotent stem cells according to claim 1 , wherein the reprogramming factor RNA further comprises at least one selected from the group consisting of GLIS1 mRNA, FOXH1 mRNA, L-MYC mRNA and p53-dn mRNA. 7 . The method for producing induced pluripotent stem cells according to claim 1 , wherein an siRNA lipofection reagent or an mRNA lipofection reagent is used in the lipofection with the reprogramming factor RNA.
8. The method for producing induced pluripotent stem cells according to claim 1, wherein at least one selected from Lipofectamine(R) RNAiMAX transfection reagent, Lipofectamine(R) MessengerMAX transfection reagent, Stemfect(R) RNA transfection reagent and ReproRNA(R) transfection reagent is used in the lipid transfection with the reprogramming factor RNA.
9. The method for producing induced pluripotent stem cells according to claim 1, wherein the number of the mononuclear cells used for the lipid transfection with the reprogramming factor RNA is 1 to 1×10 8 . 10 . The method for producing induced pluripotent stem cells according to claim 1 , wherein the amount of the reprogramming factor RNA used for the lipid transfection with the reprogramming factor RNA is 5 ng to 50 μg each time. 11 . The method for producing induced pluripotent stem cells according to claim 1 , wherein the amount of the lipid transfection reagent used for the lipid transfection with the reprogramming factor RNA is 0.1 μL to 500 μL per time. 12 . The method for producing induced pluripotent stem cells according to claim 1 , wherein the lipid transfection with the reprogramming factor RNA is performed for 0.1 hour or longer and 24 hours or shorter at a time. 13 . The method for producing induced pluripotent stem cells according to claim 1 , wherein the lipid transfection with the reprogramming factor RNA is performed multiple times. 14 . The method for producing induced pluripotent stem cells according to claim 1 , wherein a culture medium used for the lipid transfection with the reprogramming factor RNA is Opti-MEM(R). 15 . The method for producing induced pluripotent stem cells according to claim 1 , further comprising separating the mononuclear cells from blood using a filter.
Citation Information
Patent Citations
Methods of preparing pluripotent stem cells
US20150232810A1
